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Corrigendum to the  
2000 Annual Report on the  
State of the Drugs Problem in the European Union 
(amended text underlined) 
 
Page 18, under sub-heading Developments in drug-related deaths 
On the first bullet point - the first sentence, must read as follows:  
In Spain, France and to some extent Germany (although a recent increase has been reported), Italy, 
Luxembourg and Austria, acute drug-related deaths have stabilised or decreased.  
 
Page 23, under sub-heading National drug policies 
The second last sentence of the paragraph starting with ‘The new elements of Germany’s’ should read: 
The policy aims to cut young people’s access to drugs by 50% by 2008.  
- the rest of the sentence being deleted. The last sentence of the paragraph must be deleted. 
 
Page 24, under sub-heading National Drug Policies 
The first sentence of the 4th paragraph, must be replaced by the following sentences: 
In Luxembourg co-ordination of drug policy has shifted from the Ministry of Justice to the Ministry of 
Health following the latest Parliamentary elections in 1999. A bill is currently under discussion to abolish 
prison sentences and reduce fines for use and possession for personal use of cannabis and derivatives, 
and to re-scale penalties for use and possession for personal use of other drugs. 
 
Page 26, under sub-heading Infectious diseases 
The last paragraph must read as follows: 
A hepatitis B vaccination programme in Austria, however, has proved successful, and Germany, 
Luxembourg and the Netherlands report similarly positive experiences, including among those at high 
risk of intravenous drug use. 
 
Page 27, under sub-heading Problem drug users 
The second sentence of the last paragraph, must read as follows: 
In Denmark, 75 % or more and in Luxembourg 82% of those admitted to treatment use several drugs.  
 
Page 28, under sub-heading Reintegration 
The last sentence of the first paragraph must read as follows:  
Greece, Spain, Ireland, Luxembourg, Austria, Portugal and Finland have intensified their efforts to assist drug 
users to (re)-integrate into society and stabilise their lifestyles.  
The last sentence of the second paragraph must read as follows:  
Greece, Spain, Luxembourg, Austria and Portugal are increasing housing initiatives for (former) users, either 
in supported accommodation, ordinary flats or with families.  
 
Page 29, on Table 1: Substitution substances used in the EU 
The first row - 'Buprenorphine', column 'Countries reporting use of the substance' must read as follows: 
Belgium, Denmark, France, Italy, Luxembourg, Austria, UK, 
In the second row - 'Dihydrocodeine', column 'Countries reporting use of the substance', the reference to 
Luxembourg is to be deleted. 
 
Page 30, under subheading Introduction of substitution treatments in the EU 
The last part of the fourth sentence must read: 
… while in Germany, proceedings to examine heroin as a pharmaceutical product were initiated in 1999. 
 
Page 30, on Table 2: Introduction of substitution treatments in the EU 
The row 'Luxembourg', column 'Introduction of other substitution substances', must read as follows:  
Mephenon (1989), Methadone (1989) (c), and Buprenorphine (2000) 
 
Comments to the information in the column ‘Germany’: 
Methadone prescription was possible before 1992, but not considered a regular drug treatment option. 
Heroin prescription has not yet been brought into practice. 
 
Page 31, on Map: An overview of substitution treatment in the European Union 
The box on Luxembourg, must read as follows: 
Mephenon, Methadone and Buprenorphine (since 2000 prescribed) 
 
The box on Germany must read as fellows: 
Buprenorphine trials in progress. A heroin trial was foreseen for 2000 but will probably be delayed until 
2001. 
 
Page 34, on Table 3: Programmes addressing the needs of female drug users 
In the row concerning Luxembourg, with column 'Drug-using mothers and their children', the correct 
symbol is: + 
In the row concerning Germany, with column ‘Pregnant women ‘, the correct symbol is: ++ 
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5With this 2000 Annual report on the state of the drugs
problem in the European Union, the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) presents to the EU and its Member States an
overview of the drug phenomenon in Europe at the start
of the new millennium. Accurate information is essential
for effective action, and by fulfilling the information
needs of decision-makers at all levels, the EMCDDA is
contributing significantly to the development of drug
policy in Europe.
The annual report — prepared in close collaboration with
the national and European Commission focal points of
the Reitox network and other key partners — is the
Centre’s main information vehicle, and the data and
analysis it contains are key for planning and implement-
ing adequate measures to counter the drug problem at
both national and EU level.
As data-collection and data-comparison methods remain
variable throughout Europe, the EMCDDA is developing
specific instruments to facilitate the analysis of drug-
related legislation, policies and strategies in all Member
States. To this end, five harmonised epidemiological
indicators of drug use — surveys of the general population,
estimates of the prevalence of drug use, demand for treat-
ment, drug related deaths and drug-related infectious
diseases — are being implemented. These indicators not
only provide vital information on key aspects of the drug
phenomenon, but also have a broader strategic value. 
The importance of evaluating the impact of policy on the
drug problem is increasingly recognised, and it is on the
basis of these five indicators that future such assessments
will be made.
At its Helsinki meeting in December 1999, the European
Council formally adopted the European Union Drugs
Strategy (2000–04). This document sets six objectives to
be achieved by the end of that period:
• to reduce significantly the prevalence of drug use 
and of new users under the age of 18;
• to reduce significantly the incidence of negative 
health consequences associated with drug use and drug-
related deaths;
• to increase substantially the number of successfully
treated addicts;
• to reduce substantially the availability of illicit drugs;
• to reduce substantially drug-related crime; and
• to reduce substantially money laundering and the illicit
traffic in precursor chemicals.
The EMCDDA, in close collaboration with the European
Commission and the EU Member States, is now putting in
place the necessary instruments and methodologies to
implement, monitor and evaluate the strategy over the
next five years.
In line with the EU’s drug-information policy, the United
Nations International Drug Control Programme (UNDCP)
is making a concerted effort — through its January 2000
‘Lisbon consensus document’ which endorses seven
harmonised key indicators — to promote at international
level an approach to data collection to complement that
pursued at EU level by the EMCDDA.
The importance of the leading-edge role the EMCDDA
plays at EU level in obtaining reliable and comparable
drug information was reflected at international level by
the Declaration of policy and fundamental principles of
the reduction of demand for drugs, adopted in the frame-
work of the United Nations General Assembly on Drugs
in June 1998. This recognition, and the growing emphasis
placed on evaluating demand-reduction activities as the
basis for any successful national or international drug
strategy, can only be seen as major steps forward in this
field. I hope that you will find this report a step in that
direction too.
Georges Estievenart
Executive Director
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Overall trends
Trends in drug use and its 
consequences
Cannabis
Cannabis remains the most widely available and
commonly used drug across the EU, with substantial
increases in use over the 1990s. Continuing rises in
countries with previously lower levels and some stabilisa-
tion in higher-prevalence countries confirm the tendency
towards convergence noted last year.
• At least 45 million Europeans (18 % of those aged 15 to
64) have tried cannabis at least once. Around 15 million
(about 6 % of those aged 15 to 64) have used cannabis in
the past 12 months.
• Use is higher among younger age groups. About 25 %
of those aged 15 to 16 and 40 % of those aged 18 have
tried cannabis. In some countries, use has doubled since
1990, in others the rise is less marked and in a few it has
stabilised.
• ‘Curiosity’ is a primary motive for trying cannabis, and
use is more experimental or intermittent than persistent.
• The increase in numbers attending treatment centres for
cannabis use noted last year is confirmed, especially
among younger clients. Additional drugs are also often
involved.
• Cannabis remains the primary drug in drug offences,
mostly for use or possession rather than trafficking.
Numbers of seizures have increased sharply since 1997.
Amphetamines and ecstasy
Amphetamines and ecstasy are the second most
commonly used drugs in Europe. Following increases in
the 1990s, ecstasy use appears to be stabilising or even
falling, while amphetamine use is stable or rising.
• Between 1 and 5 % of those aged 16 to 34 have taken
amphetamines and/or ecstasy. Rates are higher in
narrower age groups, but rarely exceed 10 %.
• The proportion of clients seeking treatment for amphet-
amine or other stimulant use is low, but increasing in
some countries.
• Drug use continues to shift away from large dance
events to more geographically diffuse club, bar and
private settings.
• A wider range of drugs and patterns of use are
observed, linked to different social groups and lifestyles.
• Both the numbers and quantities of amphetamine
seizures stabilised in 1998. Ecstasy seizures have been
stable since 1997, although the quantities involved
fluctuate.
Cocaine
While cocaine is less commonly used than amphet-
amines or ecstasy, its use is rising — particularly among
socially active groups — and spreading to a broader
population.
• Between 1 and 6 % of those aged 16 to 34 and 1 to 2 %
of schoolchildren have tried cocaine at least once,
although some surveys show levels of up to 4 % among
15 to 16-year-olds.
• Higher levels of use are found among socially outgoing,
employed young adults in urban centres.
• Cocaine tends to be used experimentally or intermit-
tently and is usually sniffed in powder form.
• Many clients treated for heroin use also use cocaine
either intravenously or smoked as ‘crack’.
2000 Annual report on the state of the drugs problem in the European Union
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• Severe problems associated with smoking ‘crack’ have
been identified, particularly among female sex workers.
• The proportion of clients seeking treatment for cocaine
use is increasing in many countries. How far this is linked
to heroin use or has developed from heavy recreational
use of other drugs is unclear.
• In 1998, numbers of cocaine seizures continued to
increase, while the quantities involved fluctuated.
Heroin
Heroin dependence remains broadly stable. Known users
are a largely ageing population with serious health, social
and psychiatric problems, although indications of heroin
use amongst some younger groups are noted.
• Heroin experience overall remains low (1 to 2 % in
young adults) and school surveys show pupils are highly
cautious about using heroin.
• Some countries report anecdotal evidence of increased
heroin smoking among young people, and some school
surveys reveal greater experimentation.
• Heroin use is reported amongst young, heavy, ‘recre-
ational’ users of amphetamines, ecstasy and other drugs.
Other high-risk groups include marginalised minorities,
homeless young people, institutionalised youth and
young offenders, prisoners (women in particular) and sex
workers.
• New clients entering treatment for heroin use are less
likely to inject and more likely to smoke the drug than
clients returning to treatment.
• Numbers of heroin seizures and the quantities involved
are stable across the EU, although variations exist
between countries.
Multiple drug use
Patterns of weekend and ‘recreational’ drug use increas-
ingly involve combinations of illicit and licit drugs,
including alcohol and tranquillisers.
• ‘Nightlife’ studies reveal heavy multiple drug use by a
minority of young people.
• Use of synthetic drugs such as ketamine and gamma-
hydroxybutyrate (GHB) is reported, but is much less
common than use of amphetamines or ecstasy.
• More significant is the increase in cocaine use, often in
conjunction with heavy alcohol consumption.
• Abuse of volatile substances (lighter fuel, aerosols, glue)
is often more common amongst schoolchildren than
amphetamines and ecstasy, and is increasing in some
countries.
Problem drug use and demand for treatment
Patterns of problem drug use — often characterised as
‘addiction’, especially to heroin — are changing across
the EU. In addition to heroin dependence, problem use of
cocaine (often with alcohol), multiple use of drugs such
as amphetamines, ecstasy and medicines, and heavy
cannabis use are emerging.
• The EU has an estimated 1.5 million problem drug —
mainly heroin — users (between two and seven per 1 000
inhabitants aged 15 to 64). An estimated 1 million are
likely to meet clinical criteria for dependence.
• The proportion of clients entering treatment for heroin
use is generally declining, while new admissions for
cocaine or cannabis use show some increases —
especially among young clients.
Drug-related deaths
The number of acute drug-related deaths (overdoses or
poisonings) has stabilised across the EU following marked
increases in the second half of the 1980s and early 1990s.
Trends vary, however, among countries.
• Stable or decreasing rates may be linked to stable or
decreasing prevalence of heroin, safer usage or increased
access to treatment, especially substitution programmes.
• Countries with previously low numbers of acute deaths
directly linked to drug administration (‘overdoses’) report
substantial rises in recent years. This may reflect
increased prevalence of problem drug use, but also
improved recording practices.
• Other countries continue to report less sharp, but
steady increases in acute deaths.
• Numbers of drug-related deaths are significantly higher
among men than women, reflecting the higher preva-
lence of problem drug use in males.
• Most acute deaths involve opiates, often in combina-
tion with alcohol or tranquillisers. Some countries report
significant numbers of deaths from volatile substances
among adolescents. Deaths from cocaine, amphetamines
or ecstasy are uncommon.
• Overall annual mortality among problem drug users
has fallen in some countries, following rises over several
Overall trends
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years. This reflects a drop in overdose and AIDS deaths
and indicates that some deaths are preventable.
Drug-related infectious diseases
Overall trends in HIV and hepatitis B and C prevalence
among injecting drug users appear relatively stable,
although some local increases in HIV infection are
reported.
• Incidence of new AIDS cases varies greatly between
countries, but generally continues to fall, probably
because of new treatments that delay onset.
• Prevalence of hepatitis C infection among drug inject-
ors is high — between 50 and 90 % — even in countries
with low rates of HIV infection.
• Trends concerning hepatitis B are difficult to identify
because the presence of antibodies may indicate vaccin-
ation rather than infection.
• Risk behaviours that may transmit infection are of
concern. High-risk groups include: young injectors not
exposed to earlier education campaigns; women, who
tend to share injecting equipment more than men; heroin
injectors who also use cocaine; and imprisoned drug
users.
Other morbidity
Possible long-term neural damage linked to heavy use of
ecstasy is a growing concern.
• Increasing numbers of studies with both animals and
humans suggest that chronic exposure to ecstasy causes
functional and morphological changes in the parts of the
brain that regulate physiological and psychological
functions such as sleep, appetite, mood, aggression and
cognition.
• Some studies report mild cognitive impairment in
heavy ecstasy users, but the scientific literature is incon-
sistent regarding other functions. Other unresolved issues
include the ‘dangerous’ dose range, frequency of use and
whether deficits are reversible.
• Use of GHB — which in small doses diminishes tension
but in marginally larger doses can cause potentially fatal
intoxications, particularly when taken with alcohol and
other sedatives — is also causing concern.
Trends in responses to drug use
Policy and strategy developments
New drug strategies have been adopted by Spain, France,
Portugal and the UK as well as by the European Union
itself.
• National drug policies are becoming more balanced in
approach, with greater emphasis placed on demand
reduction relative to supply reduction.
• The drug problem is increasingly viewed in a broader
social context and common aims include drug 
prevention, reduction of drug-related harm and crime
deterrence.
• Accurate scientific evidence, clear objectives, measura-
ble performance targets and evaluation are key to these
strategies.
• Depenalisation of drug use offences is becoming more
common. The consensus is emerging that drug users
should not be imprisoned because of their addiction, and
alternatives provided in law are increasingly imple-
mented.
Prevention
Drug prevention in schools, recreational settings and
among high-risk groups is a priority in all EU Member
States.
• School drug-prevention programmes combine informa-
tion for pupils with training in life skills such as self-
assertiveness. Peer-group approaches actively involve
young people in implementing prevention activities in
their schools.
• Specific training and guidelines for teachers, as well as
initiatives targeting parents, are increasingly being 
developed.
• Use of the Internet as an educational tool for pupils,
teachers and parents alike is growing.
• Drug-prevention training for youth workers, night-club
and bar staff is being introduced in some countries.
• Prevention of synthetic drug use is becoming more
professional, combining information, outreach work,
counselling and sometimes pill testing.
• Local cross-sector youth policies are being developed
to meet the needs of high-risk groups.
2000 Annual report on the state of the drugs problem in the European Union
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• Evaluation methodology to assess outreach work with
high-risk groups is urgently needed and the EMCDDA is
developing guidelines to bridge this gap.
Reducing the harmful consequences 
of drug use
Reducing the harmful consequences of drug use is key to
the drug strategies of many Member States.
• Syringe-exchange programmes are expanding across
the EU and activities are intensifying to counter falling
awareness of the risks of injecting.
• Outreach work and low-threshold services are growing
as a complement to conventional drug-treatment centres.
• ‘Users’ rooms’, where drugs can be consumed under
hygienic and supervised conditions, remain controversial
and a study funded by the European Commission is
evaluating their effectiveness.
Treatment
To cope with the growing numbers and divergent needs
of those seeking treatment for drug use, diversified
patterns of care are being developed throughout the EU.
• Cooperation has increased between youth and social
services and conventional drug services, which alone are
often inadequate to treat new drug-use patterns and new
target groups.
• Specialised services for women exist across the EU,
many specifically targeting pregnant women and mothers
with children, as well as female sex workers.
• Public-health and psychiatric services are increasingly
involved in the treatment of multiple-drug use.
• Substitution treatment is expanding — including in
prisons — both in terms of the numbers of clients and the
substances used.
• Awareness of the need for adequate after-care for drug
users leaving treatment or prison — or for those in long-
term substitution treatment — has risen considerably.
• A large proportion of the prison population are drug
users and treatment is increasingly provided to avoid
relapse into illegal drug use and crime.
11
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Prevalence and patterns 
of drug use
Prevalence of drug use
Drug use in the general population
National surveys of drug use in the general population
were conducted in 11 Member States during the 1990s.
These surveys provide useful data on substances such as
cannabis, whose use is relatively common and not highly
stigmatised, but are less reliable for more hidden patterns
of use, such as heroin injection.
Direct comparisons between levels of use in Member
States should be made with caution, especially where
variations are small. Social differences (such as level of
urbanisation) or cultural factors (including attitudes to
drugs) may have a significant influence, even when
survey methods are similar.
Patterns of drug use
Cannabis is the most frequently used substance in the EU.
Lifetime experience (any use during a person’s lifetime) in
the adult population ranges from 10 % in Finland to 20 or
30 % in Denmark, Spain and the UK (Figure 1).
Amphetamines are generally used by 1 to 4 % of adults,
but by up to 10 % in the UK. Ecstasy has been tried by 0.5
to 4 % of European adults and cocaine by 0.5 to 3 %.
Experience of heroin is harder to estimate because of its
low prevalence and more hidden nature, but is generally
reported by under 1 % of adults.
Illegal drug use is more concentrated among young adults
aged 16 or 18 to 34 or 39, with rates up to double or
more those of the whole adult population (Figure 2). In
Finland and Sweden, 16 to 17 % of young adults have
used cannabis, while in Denmark and the UK the figure is
about 40 %. Amphetamines and ecstasy have been tried
This chapter gives an overview of the prevalence, patterns and 
consequences of drug use across the EU based on surveys, routine statistics 
and other research. Emphasis is placed on national data, which may mask 
local or emerging phenomena.
Notes: (1) Data are from the most recent national surveys available in each country.
(2) The age range is from 15 to 18 to 59 to 69. Variations in age ranges may influence disparities between countries.
Sources: Reitox national reports 1999, taken from population survey reports or scientific journal articles.
Lifetime experience of cannabis, amphetamines and cocaine among adults in some EU countries,
measured by national population surveys, 1994–98
Fig. 1
Cannabis
Amphetamines
Cocaine
Cannabis is the most commonly-used illegal drug in the EU
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Notes: (1) Data are from the most recent national surveys available in each country.
(2) The age range is from 15 to 18 to 59 to 69. Variations in age ranges may influence disparities between countries.
Sources: Reitox national reports 1999, taken from survey reports or scientific journal articles.
Lifetime experience and last-12-months prevalence of cannabis use among adults in some EU countries,
measured by national population surveys, 1994–98
Fig. 4
Recent drug use is much lower than lifetime experience
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by 1 to 5 % of young adults, although UK figures are 16
and 8 % respectively. Cocaine has been used by 1 to 6 %
of young European adults.
Available data from some countries reveal much higher
drug use in urban areas, although some diffusion into
rural areas may also be occurring (Figure 3). Variations in
national figures can be conditioned to a large extent by
the relative proportion of a country’s rural and urban
populations — countries with a high proportion of urban
population tend to have higher overall national drug-use
figures.
Lifetime experience is a poor indicator of recent drug use
since it includes all those who have ever tried drugs,
whether only once or some time ago. Use during the
previous year (last-12-months prevalence) is a more
accurate measure of recent use (Figure 4).
Last-12-months cannabis use is reported by 1 to 9 % of
European adults, and by 2 to 20 % (although mostly
under 10 %) of young adults. Use of other illegal
substances rarely exceeds 1 % among adults and is under
3 % among young adults.
Some surveys indicate that most people who used drugs
recently tended to do so occasionally (Figure 5).
Developments in drug use
While several countries conducted more than one
population survey in the 1990s, only Germany, Spain,
Sweden and the UK carried out series of comparable
surveys.
Lifetime experience of cannabis increased over the
decade in most countries, and levels appear to be
converging. Where prevalence was low early in the
decade (for example, in Greece, Finland and Sweden),
increases have been proportionally greater than where
Source: UK national report 1999, taken from Ramsay, M., and Partridge, S., Drug misuse
declared in 1998: Results from the British Crime Survey (London: Home Office, 1999).
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Last-12-months prevalence of ecstasy and cocaine use
by age group in England and Wales, 1998
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Source: Finnish national report 1999, taken from Partanen, J., and Metso, L., 'Suomen toinen
huumeaalto’ (the second Finnish drug wave), Yhteiskuntapolitiikka (2) 1999.
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by level of urbanisation, 1998
Fig. 3
Illegal drug use is higher in urban areas
Prevalence and patterns of drug use
13
ately — but not consistently — over the 1990s as a
whole, with ecstasy use more evident than amphetamine
or cocaine use among young adults overall.
Drug use in the school population
School surveys were conducted in most countries in the
1990s, many as part of the European school survey
project on alcohol and other drugs (ESPAD). Studies were
carried out in 1995 and again in 1999, focusing on
lifetime experience of drugs among 15 to 16-year-olds,
but direct comparisons should be made cautiously (1). As
with adults, lifetime prevalence rates are indicative of
experimentation. Apart from methodological and contex-
tual variations, small disparities in age among this group
have a major impact on figures.
Patterns of drug use
Cannabis is the most widely used illegal substance
among schoolchildren. Lifetime experience ranges 
from 5 to 7 % in Portugal and Sweden to 30 to 40 % 
in Ireland, the Netherlands and the UK. In some
countries, however, solvent use is more common in 
this age range (Figure 7).
Amphetamine experience is reported by 1 to 7 % of
schoolchildren and ecstasy use by 2 to 8 %, while figures
for cocaine are between 1 and 4 %. Some UK surveys
report higher use of amphetamines and ecstasy.
Developments in drug use 
Lifetime experience of cannabis among schoolchildren
increased substantially during the 1990s in almost all EU
countries. While use of solvents, amphetamines, ecstasy
and cocaine also rose, their prevalence remains much
lower than for cannabis.
Source: Reitox national reports 1999, taken from survey reports or scientific journal articles.
Although increasing numbers of people have tried cannabis, the number of current users is not rising at the same rate
Evolution of lifetime experience and recent (last-12-months) use of cannabis in some EU countries
during the 1990s, measured by national population surveys
Fig. 6
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Lifetime experience
Last-12-months prevalence
(1) All figures for schoolchildren presented in this report refer to 15 to 16-year-olds, for consistency with the ESPAD studies. 
Results of the 1999 study are not yet fully available.
Frequency of drug use (per year) among last-12-months
users of cannabis, ecstasy and cocaine, former West Germany, 1997
Fig. 5
Source: German national report, 1999, taken from Kraus, L., and Bauernfeind, R.,
Representative survey on the consumption of psychoactive substances in the German
adult population 1997 (Munich: Institute for Therapy Research, 1998). The frequencies
were regrouped by the EMCDDA from the original distribution. Percentages expressed
as valid percentages, excluding the ‘no answer’ (cocaine 17.5%, ecstasy 2.2% and
cannabis 0.7%).
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The most common illegal drugs are generally used intermittently, rather than frequently
1 to 9 times
10 to 59 times
60 to 199 times
200 or more times
initial prevalence was higher (for example, in Denmark,
Germany and the UK).
Increased lifetime experience of cannabis does not neces-
sarily imply a parallel growth in recent use (Figure 6).
Last-12-months prevalence has generally risen much less
than lifetime experience, implying that the reported
increases are mainly in occasional use and that most
experimenters do not seem to continue to use in the
longer term.
Trends in use of other substances are more difficult to
track because prevalence is lower. Well-documented
developments, such as increased recent ecstasy use
among groups of young people, become diluted in figures
covering the whole population. In some countries,
amphetamine, ecstasy and cocaine use increased moder-
2000 Annual report on the state of the drugs problem in the European Union
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National estimates of problem drug use
Methodology and definitions 
‘Problem drug use’ is defined here as ‘intravenous or
long-duration/regular use of opiates, cocaine and/or
amphetamines’. This operational definition excludes
ecstasy and cannabis and irregular use of any drug.
National estimates are for 1996 to 1998 except for Austria
(1995) and Sweden (1992), where more recent data were
lacking (Figure 8).
Prevalence rates have been recalculated for the 15 to 64
age group, and so are not directly comparable with the
EMCDDA’s 1999 annual report. Estimates are mainly
based on statistical models incorporating drug-related
indicators and include:
• a multivariate indicator method;
• capture-recapture;
• three multipliers based on police data, treatment data
and mortality rates; and,
• a multiplier method using back-calculated numbers of
intravenous drug users (IDUs) with HIV/AIDS in combin-
ation with HIV/AIDS rates among IDUs.
The range in Figure 8 is based on the lowest and highest
figures per country obtained by different methods.
Techniques do not always refer to the same target group,
for example back calculation only covers IDUs. While
the lower figure of a range defines intravenous opiate use,
the upper figure includes other forms of problem drug
use, such as non-intravenous regular consumption of
opiates, cocaine or amphetamines.
Italy applied five methods, Denmark, Germany, France,
Ireland, Finland and the UK applied three, Spain,
Luxembourg and the Netherlands used two, while
Belgium, Austria, Sweden and Norway could only apply
one. Using several independent methods allows cross-
validation of single estimates and could lead to more
reliable overall estimates. However, comparing between
countries is still not straightforward as most countries
could not apply all methods.
National prevalence estimates
Despite the limitations, prevalence rates seem highest in
Spain, Italy, Luxembourg and the UK (about five to seven
problem drug users per 1000 inhabitants aged 15 to 64,
ranging from 2.3 to 8.9) and lowest in Belgium, Germany,
Among schoolchildren, use of solvents can be more common than use of cannabis
Lifetime experience of cannabis, solvents and ecstasy among 15 to 16-
year-olds in some EU countries, measured by national school surveys
Fig. 7
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Notes: (1) Data are from the most recent national school surveys available.
(2) The countries presented here illustrate divergent patterns of drug experience
among schoolchildren. Other Member States may have higher or lower levels of
cannabis, solvent and ecstasy use.
Sources: Reitox national reports, taken from survey reports or scientific journal articles.
Notes: (1) All estimates are based on a 12-month period between 1996 and 1998, except for Austria (1995), Ireland (1995–96) and Sweden (1992). Greece and Portugal were unable to provide estimates.
(2) Belgium: estimate includes only IDUs and thus underestimates problem drug use; Ireland: the police data included 7% non-opiate users, 10% identified because of possession (not necessarily
users) and 5% identified by unspecified means.
(3) Sweden (1992): 1 700 to 3 350 heroin addicts; 8 900 to 12 450 other addicts, mostly amphetamine injectors (excluding cannabis addicts).
(4) Where available, estimates are given as the range of the lowest and highest results from independent calculations. The differences depend on data sources and assumptions; see the statistical
tables at www.emcdda.org.
Source: EMCDDA project CT.99.RTX.05, coordinated by the Institute for Therapy Research, Munich.
Prevalence of problem drug use appears to be relatively similar in most countries
National prevalence estimates of problem drug use
in the EU and Norway, 1996–98
Fig. 8
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the Netherlands, Austria, Finland and Sweden (about two
to three per 1000, ranging from 0.5 to 5.7). Intermediate
rates are reported in Denmark, Spain, France, Ireland and
Norway. Portugal and Greece were unable to provide
estimates.
These rates suggest little direct association between
prevalence of problem drug use and national drug policy,
since countries seem to have similar, often moderate,
levels of use whether their policies are more liberal or
more restrictive. Drug policies may, however, be signifi-
cant in minimising some consequences of problem use,
such as infections and overdoses.
Demographic variables, such as age structure, population
density and urban–rural ratios, may also affect preva-
lence, and socioeconomic factors, like unemployment,
education or income, correlate with prevalence levels in
some, but not all, studies. Factors relating to geographic
diffusion, such as trafficking routes, may also have an
influence (see box above).
Health consequences of drug use
Demand for treatment
Characteristics of clients entering treatment, such as the
proportion of injectors or opiate users, are potential
indicators of wider trends in problem drug use. Biases
may, however, arise, such as over-representation of 
injectors because of their greater need for treatment or
under-representation of cocaine users because of a lack
of treatment services.
Patterns of drug use among treated clients
Despite differences in treatment policies and recording
practices, both common and divergent features are
observed across Europe which cannot be attributed to
methodology.
Between 65 and 95 % of clients are admitted to treatment
for opiate (mainly heroin) use. Figures are lower only in
Belgium’s Flemish Community, Finland and Sweden.
Cocaine is the main drug in under 10 % of treatment
admissions, except in Spain (11 %) and the Netherlands
(17 %). Cocaine is often a secondary drug of clients
treated for heroin (15 to 60 % where data are available).
Amphetamines, ecstasy and hallucinogens are the main
drug in less than 1 to 2 % of treatment admissions,
although figures for amphetamines are higher in Belgium’s
Flemish Community, Finland, Sweden and the UK.
Cannabis is the primary drug in up to 10 to 15 % of
admissions, rising to around 20 % in Belgium’s Flemish
Community, Denmark and Finland, and is often a
secondary drug amongst opiate clients. Cannabis clients
are much younger than opiate clients (Figure 9), suggest-
ing groups with different social and personal profiles.
Geographic spread of problem heroin use in Italy
In Italy, the heroin epidemic led to an increased demand
for treatment for problem heroin use during the early
1990s. This demand is indirectly reflected by the preva-
lence of clients in treatment, which shows a spread from
north to south and from border
regions to the interior.
By 1996, the epidemic had
stabilised and even decreased in
regions where it had originally
increased rapidly. Prevalence of
clients in treatment continued to rise in other areas where
it had remained low in the early 1990s.
The geographic spread of problem heroin use in Italy
seems to have followed the main drug trafficking routes
(for example, from the Balkans via Greece to Puglia), as
well as moving out from large cities to smaller towns in
rural areas.
Source: EMCDDA project CT.98.EP.04, coordinated by Keele University,
UK. Map provided by the University of Rome, Tor Vergata.
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The proportion of injectors among clients in treatment
varies markedly, from 14 % of heroin users in the
Netherlands to 84 % in Greece. France, Italy and
Luxembourg report over 70 % of injectors among opiate
clients, while in other countries figures range from 30 to 60
%. Reasons for these differences are not yet clear, but
could include local or cultural traditions, or market factors
such as the relative availability of smokable or injectable
heroin.
Clients entering treatment tend to be males in their 20s or
30s. Ireland has the lowest mean age (24.3 years) and
Denmark the highest (32.5 years).
Developments in the profile of treatment admissions
Despite substantial improvements in treatment-data
collection, few countries can yet identify consistent
trends. Instead, characteristics of first-time clients are
often compared to the whole treated population to
identify tendencies.
Many Member States report a moderate increase in the
proportion of cannabis and cocaine clients in recent
years with a parallel decrease in the proportion of opiate
cases (Figure 10). The proportion of amphetamine clients
is low, but higher amongst new clients. While these varia-
Source: EMCDDA project CT.98.EP.10, coordinated by the Institute for Therapy Research, Munich.
Age range
Age range
Age range
Age range
Age distribution of clients admitted to treatment
for cannabis or opiate use in several EU countries (1997 data)
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Source: Reitox national reports 1999, taken from national treatment reporting systems.
Cannabis
Cocaine
Clients admitted to treatment for cannabis and cocaine use
in several EU countries (1998 data)
Fig. 10
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tions may indicate real developments, the relevance of
increases in cannabis and cocaine clients may in part
reflect decreases in the number of opiate cases among
new treatment clients.
The proportion of injectors among treated heroin users
fell in several countries during the 1990s and is not
increasing. The proportion of injectors among new heroin
clients compared to all heroin clients is also markedly
lower in all countries where data are available (Figure
11). New clients more often smoke or ‘chase’ heroin, and
a sizeable proportion who do not currently inject previ-
ously did so. While this indicates changing consumption
patterns, some smokers may become future injectors.
Drug-related deaths 
Methodology and definitions 
National statistics on drug-related deaths mostly refer to
Effect of different definitions on estimates of acute drug-related 
deaths in some EU countries
Notes: Data are taken from general mortality registries.
Definition A: drug psychosis, drug dependence, non-dependent drug abuse and
accidental poisoning caused by use of opiates, cocaine, stimulants, cannabis or
hallucinogens.
Definition B: A plus intentional poisoning or undetermined poisoning caused by use of
the same drugs of abuse.
Definition C: B plus deaths caused by the use of barbiturates, benzodiazepines, other
sedatives and hypnotics.
Source: EMCDDA project CT.98.EP.11, coordinated by the Trimbos Institute, Utrecht.
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Effect of different definitions on estimates of acute
drug-related deaths in some EU countries
Indexed change over a restrictive definition (A = 100%)
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according to definitions A, B and C
The use of restrictive or more inclusive definitions of
drug-related deaths within the same country leads to very
different estimates.
Definitions A, B and C were developed for methodo-
logical purposes as part of EMCDDA project CT.98.EP.11.
They refer to cases whose underlying cause of death
corresponds to International Classification of Diseases
9th edition (ICD-9) codes. External causes of death
(poisoning) were extracted in combination with nature of
injury codes to indicate the relevant drug of abuse.
The more restrictive definition A was made equal to 
100 % in each country, and the more inclusive definitions
B and C were expressed as percentages of A.
Current ‘national definitions’ of drug-related deaths do
not, however, correspond exactly to the A, B or C groups
given here. Dutch and UK national definitions, for
example, give fairly similar results to definition A,
whereas Sweden’s definition provides data in between
those for definitions B and C. In Sweden, cases are also
selected using both underlying and contributory causes of
death, and not only underlying causes as in the EMCDDA
project. This results in a higher ‘national’ estimate, since
not only acute deaths (overdoses), but also indirect drug-
related deaths may be included.
Even when the same set of codes (EMCDDA A, B or C) are
applied, population rates may still not be fully compar-
able due to differences in autopsy rates or the use of
forensic information in codifying the death.
acute deaths directly linked to drug administration
(‘overdoses’), although Denmark, Germany, Portugal and
Sweden use somewhat wider definitions. Deaths
indirectly associated with drug use (deaths from AIDS,
traffic accidents, violence or suicide) are assessed differ-
ently and are not discussed here.
Direct comparisons of drug-related death statistics
between countries are, however, misleading because of
the lack of harmonised definitions and methodologies.
The EMCDDA is collaborating with Eurostat, the World
Health Organisation and EU Member States to improve
this situation (see box above). If definitions and methods
remain consistent within countries, however, the statistics
can indicate trends over time.
Features of drug-related deaths
Opiates are the main drug recorded in most drug-related
deaths. The presence of other substances, particularly
A B C
Belgium (1994) 0.9 1.2 2.1
France (1997) 0.3 0.3 0.7
Netherlands (1995) 0.2 0.5 0.8
Sweden (1996) 1.5 1.9 3.6
UK (England and 
Wales – 1998) 2.2 2.7 2.9
Source: Reitox national reports 1999, taken from national treatment reporting systems.
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alcohol and benzodiazepines, increases the risk of death
in opiate intoxication. Many such deaths occur up to
three hours after use, however, making medical interven-
tion possible. Acute deaths related solely to cocaine,
amphetamines or ecstasy are unusual, despite the publi-
city they receive.
Most opiate deaths occur among injectors in their late
20s or 30s, usually after several years of use. As with
clients entering treatment, a clear ageing trend is
observed among deceased opiate users in many EU
countries (Figure 12).
The potential role of methadone in drug deaths has been
highlighted in some countries. Research shows that substi-
tution treatment reduces the risks of drug-related death.
However, since methadone substitution has increased
substantially in Europe (see Chapter 4), toxicological
examinations of overdoses, AIDS deaths or accidents
increasingly indicate the presence of methadone, regard-
less of whether there is a causal relationship. Some local
studies suggest that acute deaths involving methadone are
particularly likely to involve therapeutic methadone that
has been stolen or diverted to the illegal market.
Developments in drug-related deaths
In many countries, acute drug-related deaths increased
markedly from the late 1980s to the mid-1990s. This rise
has since stabilised in the EU as a whole, but divergent
national trends can still be identified.
• In Spain, France and to some extent Germany (although
a recent increase was reported), Italy and Austria, acute
drug-related deaths have stabilised or decreased. This
may reflect levels of problem drug use, reduced injecting
and/or increases in access to treatment, including substi-
tution treatment.
• Following few deaths in the early 1990s, Greece,
Ireland and Portugal have since reported substantial
increases. These may be related to rising heroin use, but
also reflect improved recording practices.
Notes: (1) Data for Italy are for 1993 and 1998, and data for Austria are for 1989 and 1998.
(2) Data for Austria refer to those aged 35 to 64, and for Germany to those aged 30 or
older.
(3) The proportions were calculated from the total of the younger and older age groups.
Source: Reitox national reports 1999, taken from national mortality registries or special
registries (forensic or police).
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• Following significant numbers of drug-related deaths in
the early 1990s, increases continue in Sweden, the UK
and, to some extent, Denmark. The reasons for this
tendency need further investigation.
Mortality among drug users
Assessing mortality and causes of death among problem
drug users facilitates the planning and evaluation of
public-health interventions and complements drug-
related death statistics. Mortality is gauged by following
groups of problem users, usually opiate users recruited
from treatment settings, over several years (cohort
studies).
Results indicate that mortality rates are up to 20 times
higher in opiate users than in equivalent age groups in the
general population. Among females, rates can be over 30
times higher than non-using women of the same age.
These high figures reflect causes such as overdoses,
accidents, suicides or infectious diseases. The mortality of
injectors is two to four times higher than non-injectors,
while that of users infected by HIV is two to six times
higher than non-infected users.
Analysis of cohorts in a multi-site study coordinated by
the EMCDDA shows substantial differences in mortality
and causes of death between locations. In cities with high
HIV infection among drug users, the impact of AIDS from
the mid-1980s has raised mortality rates. In Barcelona
(Figure 14), mortality reached over 50 per 1 000 users per
year from 1992 to 1996 before falling markedly, reflect-
ing a drop in AIDS deaths (probably because of new anti-
retroviral treatments) and, to a lesser extent, in overdose
deaths.
Drug-related infectious diseases
HIV and AIDS
Significant differences in prevalence of HIV infection
among drug injectors — from 1 % in the UK to 32 % in
Spain (Figure 15) — cannot be explained by differences
in sources and data-collection methods.
Since the mid-1990s, HIV prevalence seems to have
stabilised in most countries after a sharp decline follow-
ing the first major epidemic among IDUs in the 1980s.
However, new infections occur continuously, counter-
balancing the decline in prevalence caused by deaths. In
some areas, prevalence may even be increasing. In
Finland, HIV cases among IDUs have increased consider-
ably since 1998 (not shown in this report). In late 1998,
local HIV prevalence in a group of addicts (mostly injec-
tors) in Lisbon was 48 %, higher than in previous studies,
suggesting recent transmission.
Note: Overdoses are defined in this cohort as deaths classified under codes E850.0 to 859.9
of the International Classification of Diseases 9th edition (ICD-9).
Source: EMCDDA project CT.98.EP.12, coordinated by the Osservatorio Epidemiologico Regione
Lazio, Rome.
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Note: Comparability is limited because figures are from different sources and reflect different
methods. For methodological notes, see the statistical tables at www.emcdda.org.
Figures for Denmark, the Netherlands and Finland and the high figures for Austria and
Portugal are local. Figures for Germany and Italy are for opiate users in treatment and
underestimate prevalence among IDUs.
Sources: For sources, see the statistical tables at www.emcdda.org.
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Incidence of new AIDS cases also varies greatly between
countries although the general trend is downward (Figure
16). This decline is probably the result of new treatments
that delay the onset of AIDS. In Portugal, rates of new AIDS
cases are not falling, possibly indicating low uptake of
treatment and/or increased HIV infection rates. The propor-
tion of IDUs among all cumulative AIDS cases also differs
significantly between countries, illustrating variations in
the relative importance of IDUs in the AIDS epidemic.
Hepatitis B and C
Hepatitis C infection in IDUs is more prevalent and
uniform across the EU than hepatitis B infection. Whereas
prevalence of hepatitis B antibodies is between 20 and 
70 %, prevalence of hepatitis C infection ranges from
about 20 to over 90 %, even in countries with low rates of
HIV infection such as Greece (Figure 17).
In most countries, increased access to sterile needles and
syringes, greater availability of condoms, HIV counselling
and testing, and substitution treatment have all helped
control HIV transmission among injectors. While such
measures can also help reduce hepatitis C infection among
injectors, they have not prevented its spread. The persist-
ence of hepatitis C infection among new injectors requires
innovative responses. An EU-wide surveillance system is
also needed.
Few new data on hepatitis B infection are available and
thus are not presented here. Prevalence of total anti-bodies
is not a satisfactory measure as it reflects vaccination as
well as past, current or chronic infection. However,
numbers of injectors with no hepatitis B antibodies
indicate a population at risk who would benefit from vacci-
nation. Those who remain infectious can be identified
using a specific serological marker (hepatitis B surface
antigen HBsAg). Data on levels of HBsAg will be included
in future annual reports.
Law-enforcement indicators
Drug-related data from law-enforcement agencies reflect
variations in national legislation as well as in resources
and priorities. Although differences in recording proce-
dures and definitions prevent accurate comparison,
tendencies are described whenever possible.
‘Arrests’ for drug offences
‘Arrests’ (2) for all drug offences in Europe have increased
steadily since the mid-1980s and markedly since 1994.
(2) Member States define ‘arrests’ for drug offences in different ways. The term may, for example, refer to suspected offenders or to 
charges for drug-law offences. 
Note: Comparability is limited because figures are from different sources and reflect different methods, and many are not national figures. Figures for Denmark, Germany, the Netherlands, Austria,
Portugal and Finland are local. For methodological notes, see the statistical tables at www.emcdda.org.
Sources: For sources, see the statistical tables at www.emcdda.org.
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Fig. 17
Rates of hepatitis C infection among injecting drug users are extremely high
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Notes: (1) Real values have been input for all countries in 1998 and for Sweden in 1997 since
the available data  do not allow moving averages to be calculated in these cases.
(2) The series is discontinued for Belgium in 1996 and 1997 as data are not available.
The 1998 value should be read as '193'.
(3) The 1998 figure for Greece relates to the number of charges made.
Source: Reitox national reports, 1999.
'Arrests' for drug offences, 1991–98
Three-year moving averages indexed (1991=100)
Fig. 18
'Arrests' for drug offences are rising in most countries
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Greece, Spain, the Netherlands, Portugal and Finland
report the highest recent increases, while in Denmark and
Luxembourg levels have stabilised.
In 1998, cannabis was the most common substance
involved in drug-related ‘arrests’, accounting for 39 % of
all such ‘arrests’ in Ireland and 85 % in France. In Italy,
Luxembourg and Portugal, 40 to 60 % of ‘arrests’
involved heroin, while in Sweden 55 % involved amphet-
amines, a marginally higher figure than for cannabis. In
the Netherlands, most drug-related ‘arrests’ involve ‘hard’
drugs (substances other than cannabis).
In all countries that penalise possession and/or use of
drugs (3), such offences predominated in 1997 and 1998
— from 61 % of all drug-related offences in Portugal to
87 % in Austria (although this figure includes trafficking
in small quantities). In Luxembourg, the majority of
‘arrests’ involve use and trafficking.
Prison data
Routine data on drug use in prison are rarely collected,
and most information comes from local ad hoc studies.
While a high proportion — up to 90 % in some cases —
of remand and sentenced prisoners are drug users,
numbers of problem drug users are lower, ranging from
20 to 50 % of the total prison population in most Member
States.
side other market indicators such as price, purity, avail-
ability and market structure. These data are still very
scarce at national level, making an accurate picture of the
drug market difficult to draw.
Cannabis
In all EU countries except Portugal, cannabis accounts for
the greatest number of seizures. Since 1985, the number
of cannabis seizures increased steadily, and more sharply
since 1997. The quantities involved have also risen —
despite a fall in 1996 — peaking at 853 tonnes in 1998.
In 1998, Spain remained the country seizing the largest
amount of cannabis, although the UK reported twice the
total number of seizures made in Spain.
Cannabis prices are generally stable throughout the EU.
In Germany, the strength of cannabis as measured by the
percentage of the psychoactive substance delta-9-tetra-
hydrocannabinol (THC) ranged from less than 3 to 20 %
in 1998 with nearly half of the hashish samples analysed
containing 6 to 9 % THC.
Heroin
Following increases from 1985 to 1991–92, both the
number of heroin seizures and the quantities involved
have stabilised throughout the EU, with some variations
between countries. The number of seizures has decreased
markedly since 1995 in Denmark, Germany, France,
Italy, Luxembourg and Austria, but has increased in
Ireland, Finland, Sweden and the UK. The quantities of
heroin involved have also fluctuated, with decreases in
Germany, France and Finland in the last three years. In
1998, the Netherlands seized one third of the total
amount of heroin in the EU, while the UK, followed by
Spain, reported the highest number of seizures.
(3) Data were not available for Denmark or Italy.
(4) For sources, see the statistical tables at www.emcdda.org.
Drug use in prison
Studies report drug use within prisons in most EU countries
(4). Some prisoners start using drugs in prison. Initiation of
injecting drug use in prison has also been reported.
Although injecting seems to be less frequent inside prison
than outside, up to 70 % of injectors in some prisons share
needles and other injecting equipment.
Notes: (1) Where data are not available, figures are under-estimates.
(2) Data on cannabis seizures in 1998 for Belgium are not available. 
(3) Data on amphetamine seizures from 1996 to 1998 for Belgium are not available and
in 1998 for Austria. 
Sources: Reitox national reports, 1999.
Quantities of cannabis, cocaine, heroin and
amphetamines seized, 1985–98
Fig. 19
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The quantities of cannabis and cocaine seized increased markedly in the 1990s
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Drug-market indicators: seizures,
price, purity
While drug seizures may indirectly indicate drug supply
and availability, they also reflect law-enforcement priori-
ties and strategies, as well as the likelihood of different
drugs being seized. Quantities seized (Figure 19) are diffi-
cult to analyse since they may fluctuate following a few
exceptionally large seizures. The number of seizures
(Figure 20), which in many countries includes a major
proportion of small seizures from the retail level, may
more accurately indicate trends in availability on the
domestic market. Seizure data should be analysed along-
2000 Annual report on the state of the drugs problem in the European Union
22
The street price of heroin appears to be remaining
constant in Belgium, Ireland and Luxembourg and is
stabilising following a decline in Germany. Spain and the
UK report increased availability of cheaper heroin, partic-
ularly ‘brown’, smokable heroin in the UK.
Heroin purity ranges from under 20 % in Germany and
Greece to 35 to 40 % in Ireland and the UK. Denmark
reports average purity of over 60 %.
Cocaine
Cocaine seizures in the EU continued to increase in 1998
to a total of 35 060. This trend is evident in almost every
Member State, but is especially clear in Spain, Ireland
and the UK. The quantities involved fluctuate, although
the general trend is upwards. Compared to 1997, the total
amount of cocaine seized in the EU in 1998 decreased by
21 % to 34 tonnes, mainly reflecting falls in Spain and
Portugal. In 1998, the largest amounts were seized in
Spain and the Netherlands.
The price of cocaine is generally stable in the EU, but
falling in Germany and the UK. Retail purity is between
50 and 60 %, except in Greece where it ranges from 5 to
10 % and Ireland which reported 38 % in 1998.
Amphetamines, ecstasy and LSD
After a steady increase since the mid-1980s, the number
of amphetamine seizures in the EU levelled off in 1998 at
about 35 000, with more than half of these in the UK. The
Netherlands and the UK account for the greatest quanti-
ties of amphetamines seized, although a 45 % decrease
in the amounts found in the UK in 1998 caused the EU
total to fall by 19 % to around four tonnes. In Finland,
Sweden and the UK, amphetamines are the second most
commonly seized drug after cannabis.
Following a steady rise since seizures were first reported
in the late 1980s to mid-1990s, the number of ecstasy
seizures fell or stabilised in most Member States in 1997
and 1998. The numbers of pills found increased markedly
to a peak of 9.9 million in 1996 before falling to 4.2
million in 1997 and rising again to 6.2 million in 1998.
The largest quantities were found in the UK, followed by
the Netherlands and France.
Both the numbers of lysergic acid diethylamide (LSD)
seizures and the quantities involved increased to 1993
but have since decreased overall, despite fluctuations in
most countries. LSD is less commonly seized than
amphetamines or ecstasy.
The prices of both amphetamines and ecstasy decreased
in the latter 1990s, but now appear to be stabilising in
some Member States.
Amphetamine purity ranges from 6 % in Ireland to 100 %
in Greece. By contrast, the composition of pills sold as
‘ecstasy’ varies considerably. While most contain MDMA
or similar substances (MDEA, MDA), they may also
include, or consist entirely of, other active ingredients
such as amphetamines or caffeine. The physical charac-
teristics of the tablets often do not indicate their 
composition since the same shape or logo may be used
for different contents.
Notes: (1) Data are not available for Greece; data are only available from 1988 for Denmark and Portugal, from 1997 for the Netherlands and from 1993 to 1996 for Finland.
(2) Data on amphetamine seizures are not available from 1996 for Belgium, and for 1998 for the Netherlands and Austria.
(3) Most of the data series for ecstasy siezures begin in the early 1990s except for Spain, France, Italy and the UK. Data are not available for 1996 and 1997 for Belgium, and for 1998 for the
Netherlands; 1998 data for Belgium include amphetamines. The number of ecstasy seizures is over-estimated from 1985 to 1994 since LSD seizures are also included in the figures for Spain.
(4) Data on LSD seizures are not available for 1998 for the Netherlands and Finland.
Sources: Reitox national reports, 1999.
Number of cannabis, heroin, cocaine, amphetamine,
ecstasy and LSD seizures, 1985–98
Fig. 20
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Cannabis is the drug most frequently seized, followed by heroin
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C h a p t e r 3
Responses to drug use
Policy and strategy developments
National drug policies
National drug policies are becoming more balanced 
in approach, with greater emphasis placed on demand
reduction relative to supply reduction. Prevention and
reduction of drug-related harm are the most common
elements, and the recently adopted strategies of 
Spain, France, Portugal and the UK — as well as the
European Union itself — demonstrate a trend towards
viewing the drug problem in a broader context encom-
passing issues of poverty, unemployment and social
exclusion.
The key elements of these drug strategies are:
• scientific analysis and evidence as a basis for decision-
making;
• clear priorities and common objectives;
• performance targets to assess progress; and
• evaluation to measure the strategy’s effectiveness.
Coordination at national, regional and local levels is
fundamental, and national coordinators both manage and
assume political responsibility for implementing policy.
In Germany, Italy and Luxembourg, as priority has shifted
from repressive policies towards prevention and care,
responsibility for drug policy has moved from the
Ministries of the Interior to the Ministries of Health and/or
Social Affairs. Drug services are increasingly integrated
into the health-care, social and criminal-justice sectors,
and networks between policy-makers and practitioners at
local level and between national, regional and local
authorities also enhance cooperation.
The new elements of Germany’s addiction policy, adopted
in February 2000, focus on reducing drug-related harm
and assisting very deprived drug users, for instance by
providing a legal framework for injection rooms. Spain’s
2000–08 strategy on drugs, adopted on 17 December
1999 by cross-party agreement, prioritises prevention by
establishing performance targets, providing for new
monitoring centres in the autonomous regions and 
creating local action plans. The French three-year plan
(1999–2001), adopted on 16 June 1999, targets young
people through evidence-based prevention, public 
information, training, treatment and new prosecution
guidelines. Portugal’s new strategy, approved on 22 April
1999, emphasises prevention, treatment and social
rehabilitation. The UK’s 1998–2008 strategy targets young
people’s drug use, access to treatment, crime reduction,
and availability/supply of drugs. The policy aims to cut
young people’s access to drugs by 50 % by 2008, and to
reduce drug-related expulsion from schools and 
absenteeism or dismissal from the workplace. In addition,
drug-related deaths are targeted to fall by 25 % by 2002.
Spain and France include both legal and illegal drugs in
their new strategies, emphasising the addictive behaviour
not the substance. This tendency has been apparent, for
example in German, Austrian and Swedish prevention
policies, since the 1980s. The Dutch National Drug
Monitor, established by the Ministry of Health, which
began overseeing drug-related issues in 1999 under the
auspices of the Netherlands Institute of Mental Health
and Addiction, has competencies in both illegal drugs
and alcohol.
This chapter presents an overview of developments in national and 
EU drug policies and strategies and discusses the issues of quality assurance 
associated with them. Responses to the drug problem in the fields of education,
health, social care and criminal justice are also assessed.
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In prosecuting drug-related offences, alternative
measures to prison are favoured in all Member States if a
custodial sentence is not strictly necessary. In parallel,
depenalisation of drug-use offences is becoming increas-
ingly common. These trends suggest a consensus that
prison is not an appropriate solution for individuals with
drug problems. Instead, treatment appears to be the
preferred response, even when the severity of the crime
makes imprisonment inevitable.
A 1998 Belgian directive stipulated that the possession of
cannabis products for personal use should be accorded
the ‘lowest priority’ in criminal justice. Similarly, a June
1999 directive of the French Minister of Justice recom-
mended prosecutors to deliver verbal warnings and
cautions rather than imprisoning drug users — especially
occasional users of cannabis — who had committed no
other related offences. In Germany, debate on the legal
status of cannabis has intensified following the request of
the Federal Constitutional Court in 1994 for uniform
criteria for prosecuting or not personal use of cannabis. In
March 2000, the UK government announced the start of
scientific trials into cannabis prescription, the results of
which are expected in 2002.
A bill is currently under discussion in Luxembourg to
depenalise use and possession for personal use of
‘reduced-risk’ substances, such as cannabis. Portugal’s
strategy also allows for depenalising drug use or possession
for personal use (5), with offences incurring administrative
sanctions (such as fines, confiscation of a driving licence or
passport), as introduced in Spain in 1992 and Italy in 1993.
Crime prevention
France’s three-year plan targets drug trafficking,
especially in synthetic drugs. In 1999, the Netherlands
attempted to increase control of illicit trafficking at
national borders, simultaneously lengthening sentences
for cannabis dealing and prohibiting indoor cultivation of
cannabis plants. In Ireland, a Crime Council was set up in
1999 to help define, inter alia, drug-related crime-
prevention policy. The same year, the Criminal Justice Act
imposed a minimum mandatory sentence of 10 years for
possession of drugs worth over EUR 12 700, although
addiction could be a mitigating factor. In Finland, a 1999
proposed amendment to the Police Act recommended
new technology for undercover operations and technical
surveillance via telecommunication systems.
Drug-related public-order disturbances, property crimes,
aggression and violence are of growing concern. An
evaluation of Dutch nuisance policy called for broader
measures targeted at heavy drug users as well as at
‘clubbers’ and the homeless.
Drug supply in prison
A June 1999 amendment to Finland’s Act on the
Enforcement of Punishments increased the powers of
prison authorities to control drug smuggling by allowing
drug tests to be carried out on prisoners suspected of
narcotic offences or of being under the influence of drugs
who receive unmonitored visits. Also in 1999, the UK
introduced measures to prevent drugs being smuggled
into prisons and young-offender institutions by banning
any visitors found with drugs.
European Union Drugs Strategy (2000–04)
The European Union Drugs Strategy (2000–04), approved
by the Helsinki European Council on 1 December 1999,
identifies six major objectives to be achieved over five
years:
• to reduce significantly over five years the prevalence of
illicit drug use, as well as new recruitment to it, particu-
larly among young people under 18 years of age;
• to reduce substantially the incidence of drug-related
health damage (such as HIV, hepatitis B and C, tubercu-
losis) and the number of drug-related deaths;
• to increase substantially the number of successfully
treated addicts;
• to reduce substantially the availability of illicit drugs;
• to reduce substantially the amount of drug-related
crime; and
• to reduce substantially money-laundering and illicit
trafficking in precursors.
Strengthening cooperation among Member States to
enhance the provisions of the Treaty of Amsterdam,
which entered into force in May 1999, and to develop
effective EU-wide law enforcement is also stressed.
(5) When an offence has been depenalised, penal sanctions can no longer be applied in response to it. Instead, the offence is subject 
to administrative sanctions, such as fines, or other limitations of certain rights, such as the suspension of a driving licence or the 
confiscation of a passport. In Portuguese, the term ‘decriminalisation’ (‘descriminalização’) has the same meaning as ‘depenalisation’
(‘despenalização’) in the sense that it is used in this report.
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The document places great emphasis on evaluation and
calls on the EMCDDA to assess the strategy’s implemeta-
tion. For the EMCDDA, this task will be complicated by
the fact that baseline figures are incomplete and some
countries do not have the data-collection or evaluation
mechanisms in place to collect reliable information.
Quality assurance
The importance of monitoring the evolution of drug
problems and establishing indicators of the delivery and
impact of strategies is increasingly recognised, as
reflected in the recent Spanish, French, Portuguese and
UK action plans, as well as in the EU strategy. In Belgium
and Luxembourg, evaluation of the national strategy is
ongoing, while a governmental commission will assess
Sweden’s national drug policy by the end of 2000.
Investment in evaluation research and training is increas-
ing across Europe. Formal quality-assurance procedures
to improve the effectiveness of drug prevention and treat-
ment — introducing accreditation schemes, monitoring
progress and providing training — are being established
in Germany, the Netherlands, Austria and the UK. Most
current evaluations concern individual prevention and
treatment programmes, but taken together they could
form the basis for more sophisticated meta-analyses.
Training for prevention and treatment specialists, but
increasingly also for non-specialists in contact with drug
problems — primary-health staff, pharmacists, teachers,
youth workers, the police, prison staff and voluntary
workers — has been intensified in many countries.
Information exchange is a prerequisite for informed
decision-making both within and between Member
States. To this end, national and regional networking is
expanding, as is use of national web sites and databases
and multinational projects such as Prevnet involving the
Netherlands, Finland and the UK. The EMCDDA’s
exchange on drug demand reduction action (EDDRA)
database, available at www.emcdda.org, is increasingly
acknowledged as an instrument of quality assurance.
Major gaps in drug research still exist in all Member
States and more funding is clearly needed in this area.
Addiction research programmes have recently been
launched or are being planned in Germany, the
Netherlands and Finland, and new professorships have
also been created in Germany, the Netherlands and
Sweden to improve the scientific basis of drug policies.
Demand-reduction responses
Prevention
Drug prevention in schools
Drug prevention in schools is a priority in all Member
States. Programmes combining information with training
in life skills such as self-assertiveness are increasingly
being established. Peer-group approaches actively
involving young people in the implementation of activi-
ties in their schools are also gaining ground in Denmark,
Italy, Austria and Sweden. Evaluations in Greece, Spain
and the Netherlands show that with proper training for
teachers and adequate support by parents and the wider
community such prevention initiatives are effective, at
least in the short to medium term.
Guidelines have been drawn up in Germany, the
Netherlands and the UK proposing appropriate ways for
schools to deal with students with drug problems.
Truancy and expulsion or suspension are undesirable
since children who are not in school are more at risk of
using drugs.
Aside from providing information, activities targeted at
parents prioritise interpersonal and communication skills.
Some of these programmes are led by professionals,
while others promote dialogue between parents.
Although evaluation of these initiatives tends to be poor,
Danish, German and Greek studies revealed that over 50
% of participants claimed their parenting skills had
improved.
In the context of reducing social exclusion, Ireland and
the UK have introduced outreach programmes to
strengthen socially vulnerable families. These initiatives
are fairly new and evaluations are not yet available.
The Internet is increasingly used as a drug-prevention
medium with youth web sites providing information and
‘chat rooms’ on drugs issues, as well as advice for
parents. Teachers can also download guidelines from the
Internet and exchange experiences through newsgroups.
Drug prevention in recreational settings
Youth workers in recreational settings such as youth
centres and sports clubs are increasingly required to be
able to intervene early if drug problems become evident.
In Germany in 1999, 1 500 youth workers based in sports
clubs attended specialist drug-prevention seminars. In
Belgium, Germany, France and the Netherlands, while
observing the overall policy of abstinence, youth workers
may advise experimental users in low-risk drug practices
to reduce the possibility of their drug use escalating.
Assessing the outcome of these programmes is difficult
2000 Annual report on the state of the drugs problem in the European Union
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since the objectives and target groups vary over time.
More questionable in terms of effectiveness and sustain-
ability are one-off events such as youth fairs or exhibi-
tions which have increased in the last few years.
‘Recreational’ drug use by young people throughout the
EU continues to move away from large dance events to
more geographically diverse clubs and bars and to private
parties. Providing information remains the most common
prevention measure across the EU, followed by on-the-
spot counselling, outreach work and crisis intervention.
Users of synthetic drugs, who often consider themselves
knowledgeable about drugs and do not perceive that their
drug use may be problematic, are seldom seen by tradi-
tional drug services and personal interventions and
outreach work seem more suited to their needs. A
separate counselling centre for synthetic drug users is
under consideration in Austria.
Night-club and disco staff can also play a key role in drug
prevention, and guidelines on dealing with drug issues —
as well as proposals for drug-prevention policies — have
been issued to club and bar staff in Ireland, the
Netherlands and the UK.
On-the-spot pill testing has been implemented in differ-
ent forms in Germany, France, the Netherlands and
Austria. Analyses of tablets sold on the ‘recreational’ drug
market have revealed that up to 19 % contain substances
such as caffeine or ephedrine or no active substance at
all. Often, however, pill-testing projects operate in a legal
‘grey zone’, since removing, analysing and storing illegal
drugs, even for test purposes, is a violation of the law. In
Austria, pill testing is being carried out as a research
study. In the Netherlands, criteria for good testing
practice have been developed clearly distinguishing the
monitoring from the harm-reduction function.
High-risk groups
Those at high risk of drug use include ethnic minorities,
socially deprived and/or homeless young people, institu-
tionalised youths and young offenders, and sex workers.
Comprehensive child and youth policies are increasingly
being developed at local level, and cross-sector coordi-
nating bodies — with financial support, methodological
advice and training from central or regional sources —
are encouraged to implement action plans based on the
needs of their communities. In Denmark, Spain, Ireland,
Finland and the UK, drugs issues are tackled in tandem
with social exclusion, petty crime, violence and public
nuisance.
The long-term nature of these projects is implicit in their
design and a key challenge is to sustain the necessary
level of cooperation. Evaluation of these community
activities is only just beginning, and school attendance
figures, police statistics and drug-treatment data can also
help to assess their effectiveness.
Specific projects targeting new young drug users are
found in all Member States. As these users often experi-
ence health, educational, criminal and social problems,
many different services are involved and cooperation
among them is vital. Early detection of patterns of new
drug use and new risk groups is also essential.
Street workers or mobile units often target young, experi-
mental problem drug users in the locations where they
congregate. In Greece and Finland, late-night cafes or
other meeting places have been set up for, or are even run
by, young people at risk. These forms of outreach work
are extremely difficult to assess, since objectives,
methodologies and actors are often not clearly defined
due to the inherent complexity of the task. Evaluation
methodology for outreach work is urgently needed and
the EMCDDA is developing guidelines to bridge this gap.
Reducing the harmful consequences 
of drug use
Infectious diseases
The emergence of HIV in the 1980s led to the introduc-
tion of syringe-exchange programmes which are now
established in all Member States, although to varying
degrees. Needle-sharing seems to have decreased in most
countries, with more syringes being exchanged. These
programmes were given greater priority in Finland in
1999 following a significant increase in HIV infection. In
Belgium, Spain and Finland, pharmacists receive special
training in health counselling related to syringe-exchange
programmes. In, for example, Spain and France, pharma-
cies fulfil the role of ‘low-threshold centres’, distributing
both syringes and substitution substances.
Data show high prevalence of hepatitis C in Europe, even
in countries with low rates of HIV infection. Not only
intensifying needle and syringe exchange, but also educat-
ing users not to share any injecting equipment, or not to
inject at all, are the only currently available preventive
measures. A recent trial to provide interferon in a low-
threshold setting in Austria has not proved successful.
A hepatitis B vaccination programme in Austria, however,
has proved successful, and Germany and the Netherlands
report positive experiences, including among those at
high risk of intravenous drug use.
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Concerns have been expressed about falling risk aware-
ness and increased risk behaviour among young injectors
who may not have benefited from education campaigns
following the upsurge of HIV in the late 1980s and early
1990s. Research published in 1998 reveals that efforts in
the UK to make IDUs aware of the dangers of encourag-
ing non-injectors to begin injecting have been effective.
Outreach work and low-threshold services
Over the past decade, outreach work and low-threshold
services assisting drug users who are not yet or no longer
in treatment have been introduced as a complement to
conventional drug-treatment centres. These services aim
to prevent further deterioration in users’ health and social
circumstances and to motivate them to seek treatment.
Mobile outreach units provide information, clean needles
and syringes, first aid, crisis intervention and services in
locations where drug users meet or to specific target
groups, such as sex workers. In France, Ireland and the
Netherlands, such mobile units may also provide
methadone.
Low-threshold services are increasing in all Member States
— although they have only recently been introduced in
Greece and Finland in response to growing concerns
about deprived drug users — and attracting growing
numbers of visitors. Depending on the specific needs of
the users and the available resources, low-threshold
services provide food, drink and hygiene facilities,
psycho-social and medical support, clean needles and
syringes, sleeping facilities and sometimes methadone.
Outreach work and low-threshold services are also
provided by organisations run by former drug users
whose advice is trusted by current users. The more estab-
lished user organisations — such as Mainline in
Amsterdam or Brugerforeningen in Copenhagen — work
with official care services and implement specific
projects, for example targeting female users.
Users’ rooms
Users’ rooms provide an environment in which drugs can
be consumed under hygienic and supervised conditions,
thus reducing the transmission of infectious diseases and
the risk of fatal overdoses. Although users’ rooms have
been established in four German cities since 1994, they
only acquired legal status on 25 February 2000 when the
narcotics law was modified and a framework regulation
was introduced providing minimum standards for equip-
ment and management. The regulation leaves the final
decision to each federal state. By contrast, such locations
have existed for several decades in the Netherlands. An
injection room is due to open in Madrid in 2000 and
decisions are pending in Luxembourg and Austria. A
study, funded by the European Commission, is currently
examining if and how users’ rooms reduce risk behaviour,
improve and maintain health and relieve the pressure on
local communities caused by open drug scenes.
Prison settings
Conditions of drug use in prisons are even more conducive
to the spread of infectious disease than conditions outside.
In 1999, the Spanish Penitentiary Institution recommended
that syringe exchange be available in all prisons in an
attempt to lessen the dangers caused by needle sharing. 
6.6 % of Spain’s prison population also receive anti-retrovi-
ral treatment. A project to reduce the transmission of infec-
tious disease, including syringe exchange, has been imple-
mented in some German prisons.
Treatment
Early stages of drug career
The numbers of those seeking treatment for ampheta-
mine, cocaine and cannabis use, as well as heroin
smoking, has risen throughout the EU. This poses a
challenge for conventional drug services that are often
inadequate to treat new drug-use patterns at an early
stage. Cooperation with youth and social services as well
as with psychiatric services has increased, for example in
Germany, the Netherlands and Austria. In the UK, 1999
guidelines for treating young people under 16 and
between the ages of 16 and 18 have been published.
Interventions targeted at ethnic minorities and immigrants
have received attention in Germany, Luxembourg and the
Netherlands in the last five years. Drug use is fairly preva-
lent in some ethnic sub-groups which make little use of
drug services either because of language problems or
cultural taboos. Promising alternatives include peer
approaches involving ethnic associations, and providing
information in appropriate language(s). Studies into this
issue are under way among the gypsy population in
Spain, the Portuguese population in Luxembourg and the
Moluccan and North African population in the
Netherlands.
Problem drug users
In all countries, drug services are dealing increasingly with
multiple-drug use. In Denmark, 75 % or more of those
admitted to treatment use several drugs. Germany reports
problem use of substitution substances such as methadone
and codeine (substitution treatment is discussed in detail
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in Chapter 4 and is not considered here).
It is not clear how drug services react to these new
challenges. National reports suggest that general psycho-
social and sometimes psychiatric treatment are the
preferred methods, although no country provides very
specific information on the methods or objectives of treat-
ment. Greece, Austria and Finland report a growth and
diversification in treatment services over the reporting
period, and Luxembourg and Portugal are planning
similar expansion. France’s three-year drugs strategy
stresses the importance of linking treatment services for
alcohol and illegal drug use. Dutch research from 1998
and 1999 indicates that combining treatment facilities
(stepped care, including aftercare) can have positive
effects on addiction and criminal recidivism. The long-
term, large-scale UK national treatment outcome research
study (NTORS) reveals that after two years, both drug-free
and methadone treatment led to substantially higher
abstinence rates, less frequent use among those still
using, with only about one fifth of the sample remaining
daily opiate users.
Dual diagnosis — the coincidence of drug and psychi-
atric problems — is increasingly perceived as a problem
in Denmark, the Netherlands and Sweden. Similarly, the
problems of ageing drug users with very poor health and
often psychological as well as social problems have to be
taken into account in countries with a long history of
problem drug use, such as the Netherlands and the UK. In
response to their increasingly significant role in a diversi-
fied care system, guidelines for general practitioners and
other public-health staff working with problem drug users
have been issued in the Netherlands and the UK.
Treatment alternatives to punishment
In general, all Member States agree that drug users should
not be imprisoned because of their addiction. A variety of
alternatives to punishment are therefore being 
implemented across Europe, ranging from performing
community tasks to outpatient or in-patient treatment (for
further details, see Chapter 4). Several studies to evaluate
these measures are under way.
Treatment in prison
In all EU countries, treatment is available for drug-using
prisoners, and in Spain, Germany and Austria use of
methadone substitution treatment in prison is growing.
Evaluations of drug treatment in prisons, however, are not
consistent. Some report substantial decreases in both
drug use and crime, while others state that more differen-
tiated studies are needed to come to valid conclusions.
Obstacles to effective treatment in prisons include
overcrowding, lack of training of prison staff — although
specialist training is available in, for example, Spain and
Italy — and lack of follow-up after release from prison.
Reintegration
Drug users who have been in prison, undergone treat-
ment or are in long-term substitution treatment often lack
basic education, professional training, employment and
housing, all factors which severely impair their rehabilita-
tion. Greece, Spain, Ireland, Austria, Portugal and
Finland have intensified their efforts to assist drug users to
(re)-integrate into society and stabilise their lifestyles.
Germany, Greece, Spain and Ireland provide both basic
education and professional training courses in crafts,
farming or computer skills. Germany, Greece, Spain,
Ireland, Austria and Portugal report subsidised employ-
ment programmes for (former) drug users, either as
specific projects to promote integration into the labour
market or as subsidised employment schemes. The
European Commission’s Integra programme supports the
rehabilitation of young people through training and
labour policy. Greece, Spain, Austria and Portugal are
increasing housing initiatives for (former) users, either in
supported accommodation, ordinary flats or with
families.
Evaluation of these aftercare programmes has been
promising and drop-out rates are low. Maybe even more
than for those leaving drug treatment, support for drug-
using prisoners on release is essential, both in order to
avoid overdoses and to promote social integration.
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Selected issues
Substitution treatment
Substitution treatment first appeared in the EU in the late
1960s in response to emerging opiate use. As such use
spread, so too did substitution services, even though their
practice varied — and still varies — considerably. Related
legislation, prescribing practices and the overall organisa-
tion of substitution services also differ substantially within
the EU.
Drug users in substitution treatment are prescribed a
‘substitute’ substance either similar or identical to the
drug normally consumed. A distinction is made between
detoxification — gradually reducing the quantity of the
drug until there is zero intake — and maintenance —
providing the user with a sufficient amount to reduce risk
behaviour and other related harm over a longer period.
Heroin (or other opiate) users are the primary clients,
with non-opiate users more often prescribed substitution
substances for detoxification purposes. This section
focuses exclusively on treatment for opiate addiction.
Substitution substances
Substitution substances are either agonists — which
activate opiate receptors in the brain thus creating the
effect of drug consumption — or agonist-antagonists —
which while also activating opiate receptors in the brain
simultaneously limit or eliminate the effects of other
opiates or opioids taken in addition. Some substances,
like buprenorphine, combine both agonistic and anta-
gonistic features. Substitution substances used to treat
heroin abuse are either opiates — substances derived
from the opium poppy such as morphine or codeine, as
well as heroin produced from morphine — or opioids —
synthetic substances with opiate-like effects, such as
buprenorphine or methadone.
Different substitution substances work for different
periods of time, and this affects how they are adminis-
tered. The longest-lasting substance is laevo-alpha-
acetyl-methadol (LAAM), which can be taken as little as
three times a week. Slow-release morphine can be given
every other day, whereas methadone and MephenonR
This chapter highlights three specific issues relating to the drug problem 
in Europe: substitution treatment; prosecution of drug-related offences; 
and the problems facing women drug users and their children.
Substitution substances used in the EU
Table 1
Notes: (a) Substitution substances reported in less than 20 cases are not included here.
(b) Maintaining a user at: 8 mg buprenorphine a day; 1 500 mg dihydrocodeine a day; 400 mg heroin a day; 350 mg LAAM a week; 10 MephenonR pills a day; 50 mg methadone a day; 
or 400 mg slow-release morphine a day.
Substitution Characteristics Countries reporting Estimated average Substance used 
substance of the substance use of the substance (a) price per week of for detoxification
treatment (EUR)(b) or maintenance
Buprenorphine Very long-acting agonist-antagonist opioid Belgium, Denmark, France, Italy, Austria, UK 65 Both
Dihydrocodeine Short-acting, semi-synthetic, ‘weak’ agonistic opioid Belgium, Germany, Luxembourg 40 Both
Heroin Short-acting, ‘strong’ agonistic opiate Netherlands, UK 200 Maintenance
LAAM Very long-acting, synthetic agonistic opioid Denmark, Germany, Spain, Portugal 45 Both
MephenonR Long-acting, synthetic agonistic opioid Luxembourg 8 Both
Methadone Long-acting, synthetic agonistic opioid All EU Member States 20 Both 
Slow-release morphine Long-acting agonistic opiate Austria 40 Both
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(methadone in pill form) must be taken daily. Heroin and
dihydrocodeine must be taken at least twice daily.
Table 1 demonstrates that methadone is still the most
commonly used substitution substance in the EU,
although it no longer has the exclusive status it once did.
Other substances have since appeared which, despite
their diverse characteristics, are used for both detoxifi-
cation and maintenance.
Introduction of substitution 
treatments in the EU
Following an experiment in 1994–97 to prescribe heroin
to chronic drug abusers mainly for maintenance
purposes, Switzerland continues to use heroin as an alter-
native to methadone. The Swiss trial led to debates about
heroin prescription in all EU Member States, and
although similar trials were proposed in many, only the
Netherlands actually launched them in 1997 while in
Germany the legal framework for such trials was
approved in 1999. French experiences with buprenor-
phine in 1996 led to similar small-scale experiments in
Denmark (1998), Germany (1999) and Austria (1997) and
to the licensing of the substance in the UK in 1999 and in
Germany in 2000. LAAM trials spread from Portugal in
1994 to Spain in 1997 and Denmark in 1998.
While Table 2 again illustrates the predominance of
methadone, it also demonstrates how long it took before
methadone was introduced in all EU countries. Although
in many countries newer substitution substances are still
only on trial, they are increasing in importance.
An evaluation of outpatient methadone treatment in
Germany from 1995 to 1999 carried out by the Institute
for Therapy Research (IFT), Munich, revealed that drug
consumption declined while social skills and relation-
ships improved over the period.
A 1997 Dutch study showed that up to 90 % of clients on
an average daily dose of 50 mg methadone also used
cocaine and heroin, and 70 % used alcohol. First results of
a study, initiated by the minister for health, into the effect
of different methadone dosages on experimental groups
show that the group receiving a higher dose became more
stable, their health and social skills deteriorated less
frequently and even improved somewhat more often.
In Austria, a 1997 evaluation reported that buprenor-
phine can be prescribed for pregnant women since
babies born to mothers taking the substance do not
demonstrate opiate-related abstinence syndromes as do
babies of mothers taking methadone.
Whereas substitution trials with LAAM in the Netherlands
failed in the early 1990s because addicts refused to
participate, Portugal reported overall positive results,
with 64 % of the 99 participants remaining in the
programme. In a follow-up of 38 patients, 61 % did not
relapse.
Extent and settings of substitution services
Despite overall expansion in the EU in the last 30 years,
substitution treatment is still scarce in some regions and
settings. Services in Greece, Finland and Sweden, for
example, have limited geographical coverage and may
not reach potential clients in other districts. Availability of
substitution treatment in prisons also varies, both
between and within Member States.
Few Member States report limited in-patient substitution
treatment, although the provision does, in theory, exist
within the EU. Instead, substitution care is almost exclu-
sively an outpatient service, possibly because outpatient
treatment is cheaper than in-patient treatment but also
because the effect on the clients’ daily life is minimal. The
outpatient setting does not, however, address the fact that
those in substitution treatment range from relatively well-
functioning often employed individuals to marginalised
and extremely disadvantaged street addicts who may
require more care than an outpatient facility can provide.
Despite substantial increases in the evaluation of substitu-
Introduction of substitution treatments in the EU
Table 2
Notes: (a) Dates refer to the year the political decision was taken to prescribe the substance.
(b) Buprenorphine is in the form of SubutexR and not TemgesicR as this only contains
small amounts of the substance.
(c) Trial only.
(d) Date not known.
Country Methadone Introduction of other substitution
treatment substances (a)
introduced
Belgium 1994 Occasional use of buprenorphine (b), 
dihydrocodeine
Denmark 1970 Buprenorphine (b, c) and LAAM (both 1998) (c)
Germany 1992 Dihydrocodeine (1985), heroin (1999) (c), 
LAAM (1999), buprenorphine (2000) (b)
Greece 1993 No other substance prescribed
Spain 1983 LAAM (1997) 
France 1995 Buprenorphine (1996) (b)
Ireland 1970 No other substance prescribed
Italy 1975 Buprenorphine (1999) (b, c)
Luxembourg 1989 Dihydrocodeine (1994) (c), MephenonR (d)
Netherlands 1968 Heroin (1997) (c)
Austria 1987 Slow-release morphine (1997), 
buprenorphine (1997) (b, c) 
Portugal 1977 LAAM (1994) (c)
Finland 1974 Buprenorphine (1997) (b)
Sweden 1967 No other substance prescribed
UK 1968 Buprenorphine (1999) (b)
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P: LAAM now prescribed
I: Buprenorphine trials
in progress
UK: Buprenorphine now
prescribed
S: Limited, but increasing 
treatment slots available 
(now 800)
A: Slow-release morphine
increasingly used
EL: Two new substitution treat-
ment units opened
DK: LAAM and buprenorphine
trials in progress
FIN: Limited substitution 
treatment available
An overview of substitution treatment in the European Union
NL: Heroin trials in progress
D: Heroin and buprenorphine
trials in progress
F: Buprenorphine use
increasing
E: Major increase in methadone use;
buprenorphine trials in progress
B: Major increase in methadone
prescription
L: Morphine, MephenonR and
dihydrocodeine prescribed
IRL: LAAM and lofexidine
under consideration
tion treatment in the past five years, most Member States
still report a lack of quality control, monitoring and
assessment of individual programmes.
Prosecution of drug-related
offences
Possession of heroin
In 11 EU Member States, the judicial authorities prosecut-
ing the possession of small quantities of heroin or similar
drugs must assess whether the substance is for personal
use or not. Possession solely for personal use is consid-
ered less serious than possession for other purposes and
the average sentence varies from administrative sanctions
— such as confiscation of a driving licence or passport —
to a fine or a custodial sentence for up to 12 months.
In practice, however, it may be impossible to define
common criteria for prosecution — even within the same
country — since the authorities must take into account
such a broad range of factors, including the specific
national drug laws, the status of the individual offender
and where and when the offence occurred.
Some common elements can, however, be identified. In
general, petty first-time offences — such as possession of
very small quantities for personal use — lead to warnings,
cautions and confiscation of the substance rather than
more severe penalties. In Denmark, however, users
possessing a single dose for their personal use may be
allowed to keep it. In these cases confiscation is seen as
counter-productive since a crime would probably have to
be committed to pay for another dose.
Given its highly addictive nature, possession of heroin is
likely to be a repeated offence, and recidivism is a major
problem. In most Member States, recidivists face harsher
prosecution measures, such as probation or custodial
sentences, when the repeat offence involves ‘consider-
able’ quantities.
Possession of drugs such as heroin is still sentenced in
markedly different ways in the EU. In Denmark, for
example, a warning or fine may be imposed. In Greece,
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possession of small amounts of cannabis may in some
cases be more strictly punished than possession of small
amounts of heroin on the grounds that as heroin is addic-
tive, the user is in greater physical need than the cannabis
user. In the Netherlands, possession of small amounts of
‘hard’ drugs for personal use is not normally prosecuted,
while in Finland those using ‘hard’ drugs will be more
often prosecuted than those using ‘soft’ drugs, but the
legal practice varies among individual courts.
Property offences
In all Member States, offences committed against
property to finance drug habits are serious crimes, and
the fact that the offender is an addict has no independent
influence. The sentence will, however, vary according to
the circumstances of both the crime and the defendant.
Addicts who steal drugs from pharmacies or property
from private homes to finance their drug use are most
likely to be prosecuted. On conviction, they might
receive a custodial sentence determined by the quantity
of the property stolen and whether any violence — a
major aggravating factor — was used. In Ireland, for
example, possession of a syringe with intention to cause
or threaten to cause injury or intimidation can lead to
between 12 months and life imprisonment. Minor theft —
such as shoplifting — or ‘petty’ theft — as defined by
national law — incur milder sentences on condition that
the defendant undergoes treatment for the addiction.
If a minor theft is committed by someone with no previ-
ous history of property crime and no severe addiction
problems, the most likely response is a conditional
sentence plus a fine, although prison is always an option.
If, however, the offender has severe addiction problems
and agrees to undergo treatment, the most likely response
is probation, a suspended sentence and treatment.
Treatment as an alternative to punishment is a core princi-
ple in most Member States and forms the basis of Austria’s
national drug policy. Probation or suspended sentences
are commonly applied and successful treatment closes the
case. In Denmark, the results of an experiment conducted
between 1995 and 1998 to treat instead of punishing
addicted offenders are cautiously positive. Although many
of the participants relapsed into drug use at least once,
none reverted to crime during the experimental period. In
Ireland, a pilot drug court programme will give courts the
power to impose treatment on addicts and full responsibil-
ity for assessing their progress. Similarly, the 1998 UK
Drug Treatment and Testing Order (DTTO) aims to reduce
crime through court-oriented treatment and rehabilitation,
which is mandated and monitored by the courts and
supervised by the probation service. Even when a custo-
dial sentence is imposed, a growing number of countries
have increased treatment facilities in prisons.
Selling drugs
Selling drugs to acquire money to finance a drug habit is
a common behaviour among users throughout Europe
and is considered a serious offence in all countries,
whatever the circumstances. However, the extent of the
crime is taken into account when imposing penalties
which vary among countries and range from fines to a
limited period in custody to life imprisonment in the UK.
Despite the very diverse data available across Europe,
several common factors can be identified that influence
the penalty for selling drugs.
Quantity and customer
In most Member States, selling only small quantities of a
drug is regarded as a mitigating circumstance compared
to large-scale trafficking. In Greece, users who exchange
small amounts of drugs amongst themselves proven to be
exclusively for their personal use may receive a six-
month prison sentence which can either be exchanged
for a fine or suspended. Drug addicts involved in traffick-
ing considerable quantities face up to eight years’ impris-
onment, whereas non-addicted offenders face life impris-
onment. In Sweden, sentences vary from between two
months and two years to up to three years depending on
the quantity of the drug sold. Non-commercial supply is a
mitigating factor in, for example, the UK.
Degree of addiction
In all Member States, the degree of the offender’s addic-
tion may influence whether or not treatment-related
measures rather than punishment are imposed.
Nature of the substance
At judicial level, a distinction is made between the more
dangerous and addictive drugs, such as heroin, and the
less harmful and less addictive drugs, such as cannabis.
In Greece, the police, in practice, have established priori-
ties targeting drug trafficking according to the dangers
associated with specific substances. Heroin is considered
the most dangerous and is prosecuted the most severely
followed by cocaine, synthetic drugs and cannabis. In
Luxembourg, the current modification of the drug law
involves re-scaling sentencing to reflect the dangers
posed by different substances.
Recidivism
Repeat offences can incur progressively heavier
sentences in almost all Member States. In Denmark,
repeated selling of very dangerous drugs can lead to up to
six years’ imprisonment. If ‘considerable’ quantities are
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involved, the sentence can be increased to a maximum of
10 years. In Luxembourg, sentences for selling any type of
drug range from one to five years’ imprisonment and/or a
fine. For recidivists, these sentences can be doubled
within the five years following the first offence. Since
selling drugs is the most common way addicts finance
their addiction, followed by minor thefts or burglaries,
addicts are most likely to be recidivists. Yet even though
such repeat offences are motivated by physical depend-
ence, the response is more likely to be a heavy custodial
sentence than treatment.
In the EU in general, although judicial authorities may
see possession of small quantities of a drug for personal
consumption as a mitigating circumstance, the line
between possession and trafficking appears to be blurred.
While distinct sentences for the two offences are applica-
ble, no adequate parameters have yet been established to
distinguish clearly between them and the same offence
could result in different outcomes. While measures such
as treatment as an alternative to prison are available in all
Member States, the efficacy of their application has not
yet been assessed at EU level.
Problems facing women drug 
users and their children
Women-specific drug issues have not, to date, been
systematically examined by EU drug-information
systems. However, most Member States do address the
needs of drug-dependent women through specialised
programmes, although their extent and focus vary.
Drug use among women
Overall, men use illicit drugs more than women.
However, differences in drug use between men and
women are complex and depend upon the specific
substance used and the user’s age, social group, educa-
tional level and geographical location. While boys tend
to use cannabis more than girls, the difference is small or
non-existent between the ages of 15 and 16. By 20 to 24,
however, there is more male than female use. Gender
differences in last-12-months prevalence and use of
specific drugs are even more marked.
Earlier experimental drug use by girls than boys is gener-
ally the result of girls having older boyfriends who may
encourage them to try drugs. As girls grow older, further
gender-related differences in drug-use patterns appear
and strengthen.
Although overall, drug use is more common among men
than women, legal, cultural, educational and geographi-
cal factors account for increased prevalence among
women. Gender variations in use are more marked where
strong legal sanctions exist, as well as among early school
leavers and rural populations. Differences are less evident
where there is widespread acceptance, and use, of drugs
such as cannabis. In Greece in 1998, drug (primarily
cannabis) use was higher among men than women. Use
by women, however, was six times higher than in 1984,
whereas use by men increased less than threefold.
In direct contrast to illegal drugs, use of medicines such
as benzodiazepines is more common among women
than men and the difference increases with age.
Compared with illegal drugs, the relatively low social
stigma associated with licit and illicit use of medicines is
notable, although the health consequences of regular use
are considerable.
The number of women prisoners in Europe is steadily
rising. In Spain, female prisoners have almost tripled
during the past 10 years. Although a smaller proportion of
convicted drug offenders are female, data from Ireland
and the UK reveal significant levels of problem drug use
among women on entry to prison, mainly involving
heroin, methadone and benzodiazepines. Treatment
facilities in women’s prisons vary and guidelines for treat-
ing benzodiazepine dependence to prevent the dangers
of sudden withdrawal do not appear to be as well devel-
oped as guidelines for treating opiate dependence.
Mortality directly related to illicit drug use appears to be
lower among women than men, even allowing for gender
differences in prevalence (on average, women account
for only 20 % of drug-related deaths). Higher mortality in
males can only be satisfactorily explained by studying the
contextual and qualitative factors surrounding drug-
related deaths.
Infectious diseases
Anecdotal reports from Germany, France, Ireland and the
UK suggest that there is some concern that HIV and hepati-
tis B infection are increasing among some female drug
users. Although no hard data exist to support this concern,
it has been suggested that it is the result of riskier injecting
behaviour by women, or of unprotected sex.
Female drug users commit less property crimes than men
and more often support their drug habits through the sex
industry — sex work is an established source of income
for up to 60 % of drug-using women. Rising HIV infection
among European women and their new-born babies led
to routine screening programmes for HIV and, in some
cases, hepatitis B and C, in antenatal services in
Germany, France, Ireland and the UK in the 1980s and
1990s. The potential of women to spread infectious
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Programmes addressing the needs of female drug users
Table 3
Notes: – No information available or no programme reported
+ At least one programme reported
++ More than one programme reported
Sources: Reitox national reports 1999; Dagmar Hedrich, ‘Community-based services for female
drug users in Europe’, Pompidou Group of the Council of Europe, unpublished report,
December 1999.
Pregnant  women Sex workers Drug-using mothers Female prisoners Schoolgirls and
and  their children adolescents 
Belgium ++ – ++ – –
Denmark ++ + + – –
Germany – + ++ + +
Greece + + + – –
Spain – ++ + + –
France + + – – –
Ireland + ++ + + –
Italy – + ++ – +
Luxembourg – + – – –
Netherlands – + + – –
Austria ++ + ++ – +
Portugal ++ + + + –
Finland – – + – –
Sweden ++ – + – ++
UK ++ ++ ++ ++ ++
diseases to their clients has always caused concern and
the connection between female drug use and sex work
has almost certainly contributed to the growth in harm-
reduction services for female sex workers and treatment
services for female drug users. A number of outreach-
work and low-threshold facilities for women have been
established providing shelter, information and practical
advice on safer sex and safer drug use. Self-help groups,
such as Mainline in Amsterdam, offer services for women
including hair-dressing, self-defence and drama.
Pregnancy and women with children
Pregnant opiate users are increasingly seen as requiring a
particularly high level of intervention and support. Most
EU countries recognise that children born to these
women may also need specific medical care. In all States,
pregnant women are offered a ‘fast track’ into drug-treat-
ment services, and in Belgium, Denmark, France, Ireland,
Austria, Portugal and Sweden specialist services have
been developed specifically for them. Detoxification is
not generally recommended for pregnant women and
substitution treatment options are under scientific review.
For many of these women, however, regular maternity
care is incompatible with their lifestyle or they fear
stigmatisation if they attend.
The growing number of children born to drug users run 
a high risk of developing drug problems themselves 
and how children are affected by parental drug use and
dependence is an emerging concern. Studies vary in both
their methods and results. Some imply that the problems
facing children of drug-using mothers are both inevitable
and multiple, while others reveal no differences in the
emotional, behavioural and learning problems of
children of drug-using mothers and children of non-drug
users in similar social settings. Other research points to
similarities between children of drug-using and alcohol-
dependent women. Mediating effects have been identi-
fied, such as modifying living arrangements, increasing
social support and providing treatment facilities.
The extent to which children remain living with drug-
using mothers varies widely in the EU and clear policies
on removing children from drug-dependent mothers are
either not yet developed or not standardised in practice.
In Denmark and Sweden, which operate foster schemes,
there appears to be a shift towards providing support to
enable drug-dependent mothers to remain with their
children, or at least to stabilise the relationship between
children and parents. The more southern European
countries — such as Greece, Spain, Italy and Portugal —
tend to rely instead on traditional extended family struc-
tures to arrange appropriate childcare.
Drug treatment
The ratio of female to male drug users in treatment tends
to be less than 1:3. Women entering treatment tend to be
younger than men and the proportion of women to men
in treatment decreases with age. This may reflect age-
related differences between men and women seeking
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enabling children to remain with their mothers.
Women-specific drug prevention
In Germany, Austria and Sweden, drug-prevention 
activities are oriented specifically towards very young
women and schoolgirls. These initiatives often focus on
female identity and how to refuse offers of drugs from
boyfriends or other male peers.
The limited information presented here demonstrates
how, in contrast to responses to male drug use which
tend to focus on the crime-related impact of such use,
responses to female drug use appear to be motivated
more by concerns about the impact of the drug use on
others: on children where the users are mothers; and on
men where the users are sex workers.
Selected issues
treatment, or it may reflect changing patterns of drug use
among women or both. Figures are generally thought to
under-represent women with drug problems. In Belgium,
a snowball survey revealed a higher ratio of female to
male problem drug users than official treatment figures. A
major reason for the low representation of women in drug
treatment relates to motherhood: between 18 and 75 %
of female clients have at least one child and are often too
occupied with childcare to follow a treatment
programme, or fear being labelled ‘unfit’ as a mother and
having their children removed if they do enrol.
Only a few countries, such as Germany and Portugal,
provide specific services in women’s prisons, even
though a high percentage of female prisoners use drugs.
In Portugal, two prisons provide kindergarten services
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The drugs problem in central 
and eastern Europe
Drug-related problems in the CEECs were generally
limited until the geopolitical changes of 1989. Increased
permeability of borders, greater movement of people and
goods and a decline in traditional social values led both to
new problems and exacerbated existing ones. Although
drug trafficking through the region increased in the early
1990s, it had relatively little immediate effect on national
drug consumption. Since then, however, the drug
phenomenon has spread through all sectors of society.
Prevalence and patterns of 
drug use
Cannabis
School surveys
Surveys of schoolchildren show that lifetime prevalence
of drug use among 15 to 16-year-olds increased signifi-
cantly between 1994 and 1999. Data on lifetime preva-
lence of cannabis use collected over several years by the
European school survey project on alcohol and other
drugs (ESPAD) reveal cannabis to be the most commonly-
used drug, although there are some variations between
countries.
Treatment demand
While most treatment initiatives in the CEECs focus 
on problem opiate users, Albania, Hungary and 
Slovakia report treatment demands for problem cannabis
use. In the Czech Republic, the number of newly 
registered problem cannabis users in treatment has 
been rising over the past four years. Greater qualitative
clinical and ethnographic research into this trend —
which has also been observed in the EU — is now
required if treatment programmes are to respond
adequately.
Overall trends
• The percentage of the general population, especially
schoolchildren, who have tried illicit drugs at least once
is increasing.
• The age of first use or first contact with both licit and
illicit substances is decreasing.
• Demand for treatment for opiate dependency is
increasing.
• Patterns of use are changing, with increased injecting
and imported heroin taking the place of locally produced
opiates.
• Drug use is spreading from major urban centres to all
regions.
• Both drug-related arrests and seizures are increasing.
The inclusion in this year’s report of data on the drugs problem in the central 
and eastern European countries (CEECs) (6) reflects the growing cooperation
between the EMCDDA and the candidate countries for accession to the EU (7). 
As cooperation with Cyprus, Malta and Turkey is still in a preliminary stage, 
this chapter focuses on the CEECs involved in the EU Phare project on drug 
information systems (8).
(6) The CEECs are Albania, Bulgaria, Bosnia-Herzegovina, Czech Republic, Estonia, Former Yugoslav Republic of Macedonia (FYROM), 
Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia.
(7) The candidate countries are Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia
plus Cyprus, Malta and Turkey.
(8) Data are taken from the EU Phare national reports on drugs 1998 and 1999 and can only be considered a summary of general
regional trends. No data are available for Bosnia and Herzegovina.
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Availability
Increasing numbers of seizures of marijuana and
cannabis plants suggest that trafficking and local produc-
tion are escalating in most countries, although this trend
could also reflect improved law enforcement.
Opiates
Treatment demand
Opiates used in the CEECs include heroin — whose use
in the region was negligible until the early 1990s — and
substances derived from domestic production, such as
‘Kompot’ or poppy straw. Morphine and other opiates,
including hydrocodeine, may be included in the second
group, but are only found in a limited number of CEECs
(hydrocodeine is only reported in Hungary).
Although data are not recorded in a systematic or
harmonised way, demand for treatment for opiate use has
clearly increased since 1993 in all CEECs.
In 8 of the 12 countries for which data are available, 70 to
90 % of registered treatment clients were opiate users in
1995 to 1998. Lower figures are reported in the Czech
Republic (17 %), Hungary (34.7 %) and Latvia (49.4 %).
Almost all countries report a decrease in the average age
of opiate users in treatment. The most at-risk age groups
are 15 to 19-year-olds and 20 to 24-year-olds, signifi-
cantly younger than in the EU.
Lifetime prevalence of drug use among 15 to 16-year-olds in four CEECs, 1994-99
Table 4
Notes: (a) Vilnius only. 
(b) Ninth to eleventh grade pupils, Klaipeda only. 
n.a. = data not available
Number of treatment demands in the CEECs since 1993 (all substances)
Table 5
Notes: (a) Data for Albania are from one single hospital.
(b) First demand for treatment.
n.a. = data not available.
Note: (a) Average for 1995 to 1998.
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Country Substance Lifetime prevalence (%)
1994 1995 1996 1997 1998 1999
Czech all illicit drugs 26.4 n.a. n.a. 43.6 n.a. n.a.
Republic cannabis 21.5 n.a. n.a. 35.4 n.a. n.a.
Hungary all illicit drugs n.a. 4.8 n.a. n.a. 12.5 n.a.
cannabis n.a. 4.5 n.a. n.a. 11.5 n.a.
Lithuania all illicit drugs n.a. 3.2 n.a. 26.0 (a) 13.3 (b) n.a.
cannabis n.a. 1.0 n.a. n.a. 27.1 (b) n.a.
Slovakia cannabis 8.1 12.4 n.a. n.a. 19.7 23.0
Country Year
1994 1995 1996 1997 1998 1999
Albania (a) n.a. n.a. 27 63 334 523
Bulgaria n.a. n.a. 254 449 n.a. n.a.
Czech Republic (b) n.a. n.a. 2 470 3 252 3 132 3 858
Estonia n.a. 246 366 755 n.a. n.a.
Former Yugoslav 82 116 242 301 431 n.a.
Republic of 
Macedonia
Hungary n.a. 2 806 3 263 4 233 7 945 8 957
Latvia n.a. 1 084 1 289 1 517 1 738 1 970
Lithuania n.a. n.a. n.a. 1 804 2 871 2 862
Poland 3 783 4 107 4 223 4 772 n.a. n.a.
Romania n.a. n.a. n.a. n.a. 646 n.a.
Slovakia n.a. 1 189 1 239 1 594 2 074 2 199
Slovenia (b) 141 187 125 309 n.a. n.a.
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In the Czech Republic, the average age of newly regis-
tered problem drug users in treatment fell from 22.8 in
1995 to 20.6 in 1998. Over 75 % of new clients began
using drugs before they were 19, and more than 12 %
before they were 15. The same trend is evident in the
Baltic States. In Latvia, 41 % of all registered clients in
treatment are under 19, and 22 % are under 15. Albania
and Hungary also report a high percentage of clients aged
15 to 19, as well as increases in those aged 20 to 24.
Intravenous drug use
Intravenous drug use is a serious problem in the region,
and is generally, but not exclusively, associated with heroin
use. Variations, however, do exist between countries.
In Albania, 87.2 % of all clients in treatment use heroin,
either alone or with other substances, yet intravenous
drug use decreased from 29 % in 1995 to 19.3 % in
1998. In the Czech Republic, by contrast, the proportion
of IDUs rose from 55 % in 1997 to 62 % in 1998.
However, despite this increase, heroin accounts for only
17 % of the total problem drug use in the country. In
1998, 26.3 % of all registered treatment clients in
Hungary were IDUs and 86 % of all heroin users
injected. In Poland, only 50 % of clients in treatment in
1997 were injectors, and this figure is reported to have
decreased significantly since then.
Heroin versus domestic substance use
Heroin consumption peaked in most CEECs between
1994 and 1995 and again from 1997 to 1998. This rise
reflects an increase in availability which in turn has led to
a drop in the use of more ‘traditional’, domestically
produced opiates.
Albania and Latvia reported a rapid rise in heroin use in
1998, while in Estonia a move away from poppy straw to
heroin was observed from 1997 to 1998. In Hungary, the
proportion of addicts treated primarily for opiate use rose
from 21.5 % in 1994 to 34.7 % in 1998. In parallel,
sedative use declined from 27.8 to 12.2 %, and volatile
substance use fell from 15.7 to 3.4 %. In Poland, the
proportion of users of home-made opiates (so-called
‘Polish’ heroin) has been decreasing markedly, while the
percentage of heroin users is increasing. Slovakia
reported an increase in heroin use among treatment
clients from 37 % in 1993 to 86 % in 1994.
Geographic and social influences
Since 1996, opiate use in the CEECs has been spreading
from predominately major urban areas to most regions. In
Slovakia, while only 35 % of heroin-dependent clients
were treated outside Bratislava in 1994, this figure rose to
47 and 60 % in 1995 and 1996 respectively.
In Poland, disparities in opiate use have been recorded
between major cities. For example, 70 % of all treatment
clients in Warsaw and Krakow are primary opiate users.
However, in Krakow the majority use home-made opiates
while in Warsaw heroin is the primary drug consumed.
Variations in use between ethnic groups have also been
reported within CEECs. In  the Former Yugoslav Republic
of Macedonia, for example, 1998 data show that young
Macedonians tend to inject heroin whereas ethnic
Albanians are more likely to smoke it. Similar differences
have been reported with the Russian ethnic minority in the
Baltic States and with the Roma community in Bulgaria.
Drug-related diseases
Although few reliable data concerning HIV, AIDS and
hepatitis B and C are available in the CEECs, the preva-
lence of risk behaviours associated with intravenous drug
use suggests that the danger of epidemics spreading
remains high.
Cocaine
Cocaine use is relatively rare in the CEECs, but as avail-
ability has increased so too have prevalence, trafficking
and seizures. Compared with other drugs, cocaine is
quite expensive and its use tends to be limited to higher-
income brackets.
Synthetic drugs
In the last four years, all synthetic drugs have grown 
in popularity — particularly in the three Baltic States, 
the Czech Republic, Hungary, Poland, Slovakia and
Slovenia — and have become an integral part of youth
dance culture.
As users of synthetic substances tend not to see
themselves as ‘drug users’ or ‘drug addicts’, and thus
rarely seek treatment, an accurate picture of the extent of
synthetic drug use in the CEECs is hard to draw. Available
data on both the number and quantities of drug seizures,
however, seem to indicate that the spread of these
substances is largely underestimated.
Use of amphetamines and amphetamine-type stimulants
is increasing in the CEECs, although patterns of use vary.
In the Czech Republic, use of pervitin, a methampheta-
mine, represents the most serious drug problem in the
country (68 % of all problem drug users). Its use almost
tripled among schoolchildren between 1994 and 1997.
In Hungary, problem amphetamine use (mostly injected)
accounts for 15.2 % of all treatment demands. In
Lithuania, amphetamines appeared on the black market
in 1996, and are consumed in tablets or intravenously. In
Poland, amphetamines are increasingly offered to young
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people who have never previously used drugs. Romania
reported significant seizures of amphetamines in 1997.
Other substances
Other substances consumed in the CEECs — although not
to the same extent in all — include sedatives and
tranquillisers, inhalants and volatile substances.
In Hungary, sedative and benzodiazepine use accounted
for 26 % of all treatment statistics in 1998, and for 17.9 %
in Romania in 1997. In Latvia in 1998, 34.2 % of all
psychotropic substance use involved volatile substances,
while sedatives accounted for 10.1 %. In Slovakia, the
proportion of volatile substance users among all treated
clients was 10 to 11 % between 1994 and 1998, while
sedative use accounted for 6 % of all demands for treat-
ment in 1998. A national survey of 15-year-olds
conducted in 1995 in Slovenia found a significant
percentage of glue and other substance abuse, as well as
of tranquillisers, particularly among girls.
Overall, drug consumption in the CEECs continues to rise.
Responses
Over the last five years, most CEECs have attempted to
counter the drug problem through institutional and
legislative measures, demand-reduction activities (prima-
rily prevention and treatment) and law enforcement.
Institutional and legislative responses
Legislative responses continue with the integration of the
acquis communautaire into the national laws of the 10
candidate countries. A wide range of new measures —
covering money laundering, control of chemical precur-
sors, alternatives to prison, and the consumption, 
production and trade in illegal drugs — as well as inter-
national conventions and reform of the penal code have
been adopted by the CEECs since 1996.
But the formal creation of a new legislative framework is
only a first step: defining how to apply new laws — as
well as allocating the funds and human resources neces-
sary to translate these principles into reality and to
monitor their implementation — remain major
challenges. In some cases, further analysis of legislative
trends and increased cooperation will be necessary to
avoid discrepancies in the policies of the EU Member
States and the candidate countries.
While inter-ministerial structures have been established to
coordinate drug-control efforts in all CEECs, frequent
reorganisations of these structures, as well as a lack of
funds, have led to the need for reinforced national coordi-
nation. Yet despite these frequent changes, sub-committees
and working groups have contributed significantly to the
preparation of draft legislative projects, as well as to draft
national drug strategies.
Many CEECs are developing multi-disciplinary drug
strategies but, because of the poor socioeconomic situa-
tion, as well as the many political and other challenges
these countries face, they have not always been able to
allocate the necessary budgetary resources for that
purpose.
Demand and supply reduction
The rise in cross-border drug trafficking, money laundering
and diversion of precursors since the early 1990s has led to
an increased emphasis on law enforcement in the CEECs.
Controls over the supply of illicit drugs have been strength-
ened with the support of the EU’s Phare programme.
Demand-reduction activities have been developed in all
CEECs with the active support of international organisa-
tions and programmes including the EU Phare technical
assistance to drug demand reduction project, the
Pompidou Group of the Council of Europe, the World
Health Organisation and ESPAD.
Many professionals working in the drugs field in the
region have received training via these organisations, and
new documents and methodological tools have been
adapted and translated from material produced in the EU.
Preventive and therapeutic programmes have also been
created, building on the expertise available in the CEECs.
But despite these efforts, drug demand reduction remains
a low priority in most CEECs, as reflected in the division
of resources between the law-enforcement and demand-
reduction sectors which favours law enforcement.
To some extent, the scarcity of resources and the difficult
socioeconomic situation within individual countries have
meant that funds provided through international support
have influenced decisions regarding which actions
should be developed. As a result, and despite the quality
of those working in the field, many such activities have
had a limited impact on the situation.
All forms of action need to be integrated into more coher-
ent and effective national and regional strategies based
on greater knowledge of the most problematic aspects of
the drug phenomenon. As a result, strengthening the
prototype national focal points in each CEEC, as well as
the participation of the candidate countries in the
EMCDDA’s activities, could significantly benefit the
decision-making process in these countries.
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EMCDDA publications 2000
Online publications
Annual publications
Statistical bulletin 
online at www.emcdda.org
(available in English)
Print publications
Annual publications
2000 Annual report on the state of the drugs
problem in the European Union
(available in all 11 official EU languages)
1999 General report of activities
(available in English, French and German)
Newsletter
DrugNet Europe, Nos 21 to 26
(bimonthly newsletter, available in English,
French, German, Portuguese)
Scientific monograph series
Methods to integrate epidemiological 
indicators to address policy-related questions
on drug use
Scientific monograph No 6
(available in English)
Evaluation: A key tool for improving drug
prevention
Scientific monograph No 5
(available in English)
Understanding and responding to drug use:
The role of qualitative research
Scientific monograph No 4
(available in English)
Insights series
Reviewing current practice in drug 
substitution treatment in Europe
Insights No 3
(available in English)
Reitox focal points
Belgique/België 
Institut Scientifique de la Santé
Publique/ Wetenschappelijk
Instituut Volkgezondheid
(Scientific Institute of Public
Health)
Denise Walckiers
Rue Juliette Wytsman 14
B-1050 Bruxelles/Brussel
Tél. (32-02) 642 50 35 
Fax (32-02) 642 54 10
e-mail: birn@iph.fgov.be
http://www.iph.fgov.be/reitox
Danmark
Sundhedsstyrelsen (National
Board of Health)
Vibeke Graff
Amaliegade 13
PO Box 2020
DK-1012 København
Tlf. (45) 33 91 16 01
Fax (45) 33 33 00 18
e-mail: vig@sst.dk kag@sst.dk
http://www.sst.dk
Deutschland 
Deutsche Referenzstelle der
Europäischen Beobachtungsstelle
für Drogen und Drogensucht
DBDD c/o IFT Institut für
Therapieforschung (German
Focal  Point of the European
Monitoring Centre for Drugs and
Drug Addiction c/o Institute for
Therapy Research)
Roland Simon
Parzivalstr. 25
D-80804 München
Tel. (49-89) 36 08 04 40 
Fax (49-89) 36 08 04 49
e-mail: simon@dbdd.de
http://www.ift.de
Greece
University Mental Health
Research Institute (UMHRI)
Greek Reitox Focal Point
PO Box 66517
GR-15601 Athens 
Tel. (30-1) 653 69 02
Fax (30-1) 653 72 73
e-mail: akokke@mail.ariadne-t.gr
http://business.hol.gr/˜umhri 
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e-mail: akokke@mail.ariadne-t.gr
http://business.hol.gr/˜umhri
España 
Delegación del Gobierno para el
Plan Nacional sobre Drogas
Ministerio del Interior
(National Plan on Drugs DGPND)
Camilo Vázquez Bello
c/Recoletos, 22
E-28001 Madrid 
Tel. (34) 91 537 27 25 
Fax (34) 91 537 26 95
e-mail: cvazquez@pnd.mir.es
http://www.mir.es/pnd/index.htm 
France 
Observatoire Français des
Drogues et des Toxicomanies
(French Observatory for Drugs
and Drug Addiction OFDT)
Jean Michel Costes
105, rue Lafayette
F-75110 Paris
Tél. (33) 153 20 16 16 
Fax (33) 153 20 16 00
e-mail: jecos@ofdt.fr
http://www.drogues.gouv.fr
Ireland
Health Research Board
Drug Misuse Research Division
Rosalyn Moran
73 Lower Baggot Street
Dublin 2
Ireland
Tel. (353-1) 676 11 76 extn 160 
Fax (353-1) 661 18 56
e-mail: rmoran@hrb.ie
http://www.hrb.ie
Italia
Presidenza del Consiglio dei
Ministri, Dipartimento per gli
Affari Sociali, Ufficio per il
coordinamento delle attività di
prevenzione e recupero delle
tossicodipendenze (Prevention
and Rehabilitation Activities
Coordination Unit, Department
for Social Affairs of the Presidency
of the Council of Ministers)
Franco Scarpino
Via Veneto, 56
I-00187 Roma
Tel. (39-06) 48 16 14 95
Fax (39-06) 48 24 934
e-mail: 
puntofocale@affarisociali.it
http://www.affarisociali.it
Luxembourg 
Direction de la Santé, Point Focal
OEDT, Luxembourg (Health
Directorate, EMCDDA Focal
Point, Luxembourg)
Alain Origer
Allée Marconi 
Villa Louvigny
L-2120 Luxembourg
Tél. (352) 47 85 625 
Fax (352) 46 79 65
e-mail: alain.origer@ms.etat.lu
http://www.relis.lu
Nederland 
Trimbos-instituut (Netherlands
Institute of Public Health and
Addiction)
Franz Trautmann
Da Costakade 45 
PO Box 725
3500 AS Utrecht
Nederland
Tel. (31-30) 297 11 86 
Fax (31-30) 297 11 87
e-mail: ftrautmann@trimbos.nl
http://www.trimbos.nl 
Österreich
Österreichisches Bundesinstitut
für Gesundheitswesen (Austrian
Health Institute ÖBIG)
Sabine Haas
Stubenring 6
A-1010 Wien
Tlf. (43-1) 515 61 160 
Fax (43-1) 513 84 72
e-mail: haas@oebig.at
Portugal 
Instituto Português da Droga e da
Toxicodependência (Portuguese Institute
for Drug and Drug Addiction)
Elza Pais
Av. João Crisóstomo, 14
P-1000-179 Lisboa
Tel. (351-21) 310 41 00
Fax (351-21) 310 41 90
e-mail: maria@ipdt.pt
http://www.ipdt.pt
Suomi/Finland
Sosiaali ja terveysalan tutkimus ja kehit-
tämiskeskus (National Research and
Development Centre for Welfare and
Health — STAKES)
Ari Virtanen
PO Box 220
FIN-00531 Helsinki
P./tfn (358-9) 39 67 23 78
F./fax (358-9) 39 67 23 24
e-mail: ari.virtanen@stakes.fi
http://www.stakes.fi
Sverige
Folkhälsoinstitutet (National Institute of
Public Health)
Bertil Pettersson
S-103 52 Stockholm
Tfn (46-8) 56 61 35 00
Fax (46-8) 56 61 35 05
e-mail: bertil.pettersson@fhi.se
http://www.fhi.se 
United Kingdom
DrugScope
Nicholas Dorn
Waterbridge House
32/36 Loman Street
London SE1 0EE
United Kingdom
Tel. (44-20) 79 28 12 11
Fax (44-20) 79 28 17 71
e-mail: nicholas@drugscope.org.uk
http://www.drugscope.org.uk/index.html
Norge (Observer)
Norwegian Directorate for the
Prevention of Alcohol and Drug
Problems
Stein Berg
PO Box 8152 Dep.
NO-0033 Oslo
Tfn (47-22) 24 65 00
Fax (47-22) 24 65 25
e-mail:
Ingvild.Hoel@RusDir.dep.telemax.no
European Commission
Directorate General Justice and 
Home Affairs Drugs Unit
JAI/A/4
Timo Jetsu
Rue de la Loi 200 (Lx-46 5/93)
B-1049 Bruxelles
Tél. (32-0-2) 29-9 57 84
Fax (32-0-2) 29-5 32 05
e-mail: timo.jetsu@cec.eu.int
http://europa.eu.int/comm/justice_home/unit/unit4_en.htm
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of 11 decentralised agencies set up by the European Union to carry out specialised technical or scientific work.
‘Established in 1993 and operational since 1995, the Centre’s main goal is to provide objective, reliable and 
comparable information at European level concerning drugs and drug addiction and their consequences’. 
Through the statistical, documentary and technical information it gathers, analyses and disseminates, the EMCDDA
provides its audience — whether policy-makers, practitioners in the drugs field or European citizens — 
with an overall picture of the drug phenomenon in Europe.
The Centre’s main tasks are:
• collecting and analysing existing data;
• improving data-comparison methods;
• disseminating information; and
• cooperating with European and international organisations and with non-EU countries.
The EMCDDA works exclusively in the field of information.
The EMCDDA online
Detailed information on drug use in Europe, downloadable publications in all 11 official EU languages, links 
to specialised drug-information centres in Europe and beyond, and free access to specialised databases can all be 
found on the EMCDDA website at  http://www.emcdda.org.
